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Abstract 
The current HIV epidemic is highlighted by the remarkable success of combination 
anti-retroviral therapy (cART). Unfortunately, life-long and continuous cART is necessary 
for infected individuals due to persistent HIV infection and rebound viremia if cART is 
interrupted. The ability of HIV to establish a reservoir within long-lived cells is a major 
barrier to improving treatment and affording a cure.  
Here, I first describe our work to characterize the HIV reservoir within 
hematopoietic stem and progenitor cells (HSPCs) and determine the contribution of 
infected HSPCs to residual viremia in vivo. We found that HSPCs bear HIV proviral 
genomes in almost half of donors tested (24 of 43). Furthermore, we found that HSPC-
derived proviral genomes are represented within residual plasma viral sequences about 3-
fold more than proviruses derived peripheral blood and bone marrow mononuclear cells. 
We also discovered that HSPC-derived proviruses that were genetically identical to plasma 
virus are very often associated with expanded clonal HIV proviruses found in peripheral 
blood and bone marrow mononuclear cells. Additionally, we identified a signature deletion 
within proviral sequences derived from HSPCs and mature PBMCs and CD4+ T cells, 
providing evidence that HIV-infected HSPCs can propagate the HIV genome to progeny 
through differentiation. This study sheds light on the heterogeneity of the HIV reservoir 
and presents evidence in support of a novel pathway for the establishment and maintenance 
of persistent HIV in vivo. 
ix 
Finally, I describe our work investigating strategies to potently reverse HIV latency 
and induce reservoir elimination using histone deacetylase inhibitors (HDIs). We 
determined that class 1-selective HDIs are superior to pan-HDIs in their ability to act 
additively with the PKC agonist bryostatin-1 to reverse latency, induce potent viral 
outgrowth, and promote elimination of latently-infected cells. We also found that pan-HDIs 
suppress potent viral reactivation; an effect that is correlated with their unique inhibitory 
effects on important pro-viral cellular factors, NF-κB and Hsp90. 
This work will significantly inform future studies that will further characterize the 
heterogeneity of the in vivo HIV reservoir and develop clinically pragmatic and effective 
latency-reversing agents that may lead to improved HIV therapy aimed at reducing the 
burden of persistent viral infection and hopefully affording a cure. 
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Chapter 1  
Introduction 
Combination anti-retroviral therapy (cART) significantly reduces morbidity and 
mortality associated with HIV infection. Nevertheless, even long-term, continuous cART 
does not cure infected individuals. The existence of long-lived reservoirs of latently-
infected cells is a major barrier to affording a cure. The goals of the work described in this 
dissertation are to gain a better understanding of the HIV reservoir and to develop strategies 
that may lead to reservoir elimination. In this chapter I will first introduce the current 
knowledge of HIV epidemiology, pathogenesis, treatment and biology. I will then discuss 
our current understanding of the HIV reservoir within infected individuals. Finally, I will 
review several pharmacologic agents that affect HIV latency and have been proposed to 
potentially reduce the viral reservoir in vivo. Therefore, in this chapter I present the 
background information necessary for the original discoveries by our group that I describe 
in chapters 2 and 3 of this dissertation. 
The beginning of the HIV pandemic 
The signs and symptoms of acquired immunodeficiency syndrome (AIDS) were 
first described in the United States of America in 1981 when an increasing number of men 
began to succumb to opportunistic infections and rare malignancies (Centers for Disease, 
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1981; Centers for Disease, 1982; Hymes et al., 1981; Masur et al., 1981). Two years later 
the causative infectious agent was identified as human immunodeficiency virus type-1 
(HIV-1; HIV) (Barre-Sinoussi et al., 1983; Gallo et al., 1983; Popovic et al., 1984). Shortly 
thereafter diagnostic tests for HIV infection were developed and public health measures 
were implemented to limit the spread of this devastating disease. By 1986 over 30,000 
cases of HIV/AIDS had been identified globally with about 60% of the documented cases 
occurring in the American population (UNAIDS, 2016). Six years after the first reports of 
patients with AIDS, the United States Food and Drug Administration (FDA) approved the 
first effective anti-retroviral drug, zidovudine (Fischl et al., 1987). It was; however, not 
until 1995 when the discovery of a mechanistically unique anti-retroviral drug was 
incorporated into a combination therapy with AZT that the era of combination anti-
retroviral therapy (cART) began. The introduction of cART dramatically changed the 
outlook on the HIV pandemic as combination therapy was able to decrease the morbidity 
and mortality associated with HIV infection by over 60% (UNAIDS, 2016). 
By the turn of the century, HIV/AIDS was the fourth most-common cause of death 
worldwide and the leading cause of death in Africa. Moreover, despite cART, cases of HIV 
infection continued to rise dramatically, especially in Africa and Asia (UNAIDS, 2016). In 
developed nations, where infected people had greater access to cART, medical 
professionals were encouraged by the remarkable success of cART in reducing viral 
replication in infected people and the entire community looked forward to what they 
believed would soon be a day where HIV infection could be cured with sufficient cART. 
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The HIV pandemic today 
Since the introduction of cART, there has been a dramatic reduction in the rate of 
new HIV infection events and of the frequency of HIV/AIDS-related deaths (Palella et al., 
1998). Nevertheless, in 2016 over 36 million people were living with HIV and 1 million 
died due to the infection. The greatest burden of the HIV pandemic today is undoubtedly 
upon those affected in Africa where access to cART is limited and the rates of infection 
are dramatically higher than in any other region (UNAIDS, 2016). 
On the other hand, in developed nations, with continuous and compliant cART, 
HIV infection can be effectively controlled to levels where even the most sensitive clinical 
assays often do not detect any evidence of viral replication or disease progression. In these 
cases, life-long cART represents the only practical option for most HIV-infected people to 
avoid recrudescence of viral replication and progression to AIDS. However, there remain 
several significant challenges to life-long cART compliance including: the life-long 
financial burden of treatment compliance, the associated side-effects of therapy, and the 
persistent social stigma. 
Clinical features of HIV infection 
Viral Transmission 
Infection with HIV often occurs through sexual intercourse, exposure to infected 
blood, or perinatal transmission (Tindall et al., 1988). The proportion of individuals who 
become HIV infected by one of these modes of transmission differs globally and is often 
related to specific risk factors such as: viral load of transmitting individuals, sexual 
behavior, male circumcision, and genetic background. The highest rates of HIV 
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transmission events per exposure occur in men who have sex with men (1 in 72 exposures) 
and intravenous drug users (1 in 150 exposures). Transmission of HIV through 
occupational exposure to HIV-contaminated body fluids is extremely low (1 in 10,000 
exposures) (UNAIDS, 2016). 
 
Natural history of untreated infection 
The acute phase of HIV infection occurs over approximately the first 3 months 
post-exposure and is characterized by a period of rapid viral replication and a precipitous 
loss of CD4+ T lymphocytes (CD4+ T cells); the main target cell of HIV (Figure 1.1a). 
Approximately 50-70% of infected individuals will experience symptoms of acute HIV 
infection, including fever, lymphadenopathy, myalgia, arthralgia, and headache (Braun et 
al., 2015; Daar et al., 2001; Niu et al., 1993). Interestingly, some studies have described a 
worsened clinical prognosis in infected people who had prolonged symptoms (>14 days) 
during the acute phase (Daar et al., 2008; Kelley et al., 2007; Lavreys et al., 2006). Within 
several weeks, infected individuals seroconvert and begin producing clinically detectable 
levels of antibodies against HIV antigen. This response, along with a robust cell-mediated 
reaction against high viral titers reduces serum viremia to a viral set point and recovers 
CD4+ T cells count nearly to a normal level (Musey et al., 1997; Pantaleo et al., 1997). 
Critically, the viral set point has been associated with prognosis of untreated disease 
(Lavreys et al., 2006; Mellors et al., 1995). Following the resolution of primary infection, 
a period of asymptomatic infection occurs where HIV and the host immune system engage 
in a dynamic competition. This period can last for months to years, during which low-level 
viral replication in CD4+ T cells causes an insidious decrease in CD4+ T cell counts at a 
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rate of about 30 to 60 cells/mm3/year (Mellors et al., 1997; Munoz et al., 1997; Phair et al., 
1992). Once below 200 CD4+ T cells/mm3, an infected person is considered to have AIDS, 
which is characterized by severe opportunistic infections and rare malignancies including: 
P. jirovecii pneumonia, candidiasis, disseminated histoplasmosis, toxoplasma encephalitis, 
and cryptococcal meningitis (Chaisson et al., 1987; Flanigan et al., 1992; Phair et al., 1990). 
When CD4+ T cell counts drop below 50 cells/mm3, generalized deficiency in cellular 
immunity is profound and infected individuals are ever more susceptible to additional 
opportunistic pathogens (Masur et al., 1989). Most individuals whose HIV infection 
progresses to AIDS, often die due to an AIDS-related illness within only 12-18 months 
(Phillips et al., 1992) (Figure 1.1a). 
 
Combinational anti-retroviral therapy 
The advent of cART dramatically changed outcomes of HIV infection. By 
combining antiretroviral agents that inhibit distinct events in the viral replication cycle, 
development of drug resistant virus is incredibly unlikely. Maintained on cART 
continuously, plasma viremia is often below the limit of detection of even the most 
sensitive clinical assays (< 50 HIV RNA genome copies/mL plasma) and patients are able 
to live relatively healthy lives (Egger et al., 2002; Hogg et al., 2001; Palella et al., 1998). 
Occasionally; however, intermittent viral “blips” (> 50 HIV RNA genome copies/mL 
plasma) can be detected in treated patients (Nettles and Kieffer, 2006; Nettles et al., 2005). 
Interruption of cART, even after years of continuous therapy, leads to a rapid rebound 
viremia (Chun et al., 1999; Davey et al., 1999; Joos et al., 2008). Thus, cART is an effective 




 A very small percentage of HIV-infected people exhibit spontaneous effective 
control of HIV infection for at least 12 months even in the absence of cART. Indeed, these 
patients are HIV-positive by standard clinical assays for antibodies against the virus but 
lack any sign of robust viral replication (undetectable plasma virus by standard clinical 
assays) and can remain so for decades (Dinoso et al., 2008; Klein and Miedema, 1995; 
Pereyra et al., 2009). These individuals, termed elite controllers, make up only about 1 in 
300 people infected with HIV (Walker, 2007). Thus far, studies with the goal to understand 
the mechanisms of this phenomenon have pointed to at least two factors that are strongly 
correlated with spontaneous control, including: asymptomatic acute infection (Madec et 
al., 2005) and the certain HLA B alleles (Emu et al., 2008). Interestingly, elite controllers 
also bear CD8+ cytotoxic T lymphocytes (CTLs) that are qualitatively more functional 
compared to CTLs from HIV-infected progressors (Betts et al., 2006; Migueles et al., 2002; 
Zimmerli et al., 2005). 
The HIV replication cycle 
HIV is a member of the Lentivirus genus within the Retrovirus family. Therefore, 
HIV virions are enveloped, spherical particles, about 100 nm in diameter that contain a 
conical protein capsid core, inside which are two copies of the single-stranded RNA 
genome (Gelderblom et al., 1987). The HIV genome is approximately 9 kilobases in size 
and encodes for 3 structural proteins (Gag, Pol, and Env), 2 regulatory proteins (Tat and 
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Rev), and 4 accessory proteins (Vif, Vpr, Vpu, and Nef) the functions of which will be 
discussed below (Figure 1.2a). 
 
Binding and entry  
HIV infection begins when subunit gp120 of the viral Env protein binds its cognate 
target cell receptor CD4 and co-receptor CCR5 or CXCR4 (Choe et al., 1996; Deng et al., 
1996; Dragic et al., 1996; McDougal et al., 1986). This initiates a conformational change 
in the Env protein, which approximates the lipid bilayers of the virion and target cell 
leading to fusion and release of the inner protein capsid core of the virion into the host cell 
cytoplasm (Wilen et al., 2012) (Figure 1.2b). 
 
Reverse transcription  
Shortly after entry, the viral capsid disassembles and the viral RNA genome is 
reverse transcribed by HIV reverse transcriptase (RT) into a complementary double-
stranded DNA molecule (Figure 1.2b) (Hu and Hughes, 2012). HIV reverse transcription 
begins at the 5’ end of the genome where the 3’ hydroxyl end of a producer-cell derived 
tRNA(Lys3) is bound to the primer binding site (pbs) of the HIV genome. Minus-strand 
cDNA [(-) cDNA] is synthesized to the end of the 5’ RNA genome. As the (-) cDNA—
RNA hybrid complex is formed, RNaseH activity of RT degrades the RNA template, 
leaving a short, single-stranded (-) cDNA molecule. Next the (-) cDNA anneals to the its 
complementary R region of the 3’ end. (-) cDNA elongation continues over the length of 
the RNA genome. Again, as cDNA—RNA hybrids are formed, RNaseH degrades the RNA 
template leaving a single-stranded (-) cDNA molecule. Critically, the polypurine tract 
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(PPT) is spared RNaseH digestion and serves as the primer for positive strand cDNA [(+) 
cDNA] synthesis, which proceeds to the 5’ end of the complementary (-) cDNA and 
extends to include complementary cDNA to the pbs sequence. Following RNaseH 
digestion of the tRNA primer the single-stranded, complementary pbs sequences of the (-) 
cDNA and (+) cDNA anneal and permit the completion of reverse transcription by 
elongation of (+) cDNA. The final product is a linear, double-stranded cDNA with long 
terminal repeats (LTRs) at either end of the genome (Figure 1.3). 
 HIV RT lacks any proof-reading activity and, as a result, is estimated to make about 
2 errors per 10,000 bases pairs, or about 2 mutations per genome (Hu and Hughes, 2012). 
Furthermore, cDNA recombinants are frequently formed during (-) cDNA synthesis. These 
recombination events allow for successful completion of reverse transcription, but may 
also lead to significant deletions, insertions, and duplications of regions of the genome 
yielding defective proviral genomes. 
 
Nuclear import and integration  
A distinguishing feature of lentiviruses is their ability to usurp host cell machinery 
to actively transport their genome across intact nuclear envelopes, thereby allowing them 
to productively infect non-dividing cells. Following reverse transcription, the viral cDNA 
genome associates with cellular and viral proteins to form the nucleoprotein pre-integration 
complex (PIC), which passes through nuclear pores into the nucleus. Once in the nucleus, 
via the activities of HIV integrase and host DNA repair enzymes, the cDNA genome is 
integrated into the host genome, often in actively transcribed host genetic regions (Craigie 
and Bushman, 2012; Lewinski et al., 2005; Marini et al., 2015) (Figure 1.2b). 
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Provirus transcription  
Once in the host genome, the integrated viral cDNA, or provirus, is dependent upon 
host cell machinery to transcribe and translate its genome. The 5’ HIV LTR serves as a 
viral gene promoter, with several DNA sequences that can be bound by host and viral 
proteins necessary for robust viral gene transcription (Figure 1.2b). Many of these factors 
will be discussed in more detail below. 
 
RNA processing and translation  
Splicing and processing events regulate the abundance of viral RNA species and 
ensures efficient and complete expression of the viral genome (Purcell and Martin, 1993). 
The first RNA species to be transcribed and processed by host spliceosomes are multiply-
spliced transcripts, which encode the viral accessory protein Nef as well as important 
regulatory proteins, Tat and Rev. Only when Tat and Rev accumulate to sufficient levels 
can they facilitate Tat-mediated transactivation of RNA polymerase II-dependent 
transcription and Rev-mediated nuclear export of unspliced HIV RNA species (Kim et al., 
1989; Klotman et al., 1991). Further discussion on the importance of Tat of Rev in 
regulating viral gene expression and HIV latency are discussed later in this chapter. 
Incompletely or singly-spliced RNA transcripts are next processed and encode the 
structural protein Env, as well as three accessory proteins, Vif, Vpr, and Vpu. Finally, 
unspliced, or full-length RNA transcripts, encode the Gag-Pol polyprotein and serve as the 
genomic RNA to be incorporated into newly forming virions (Purcell and Martin, 1993) 
(Figure 1.2b).  
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Virion assembly, release, and maturation  
HIV Gag is both necessary and sufficient to form virus-like particles. Gag is 
synthesized as a polyprotein, which accumulates on the cytoplasmic side of the cell 
membrane and multimerizes with other Gag polyproteins to form a budding structure 
(Freed, 1998). Gag is also essential for loading of specific cargo into the forming virus 
particle including Env, Vif, Vpr, the Gag-Pol precursor, and two copies of the viral RNA 
genome (Clever et al., 1995; Cosson, 1996; Muller et al., 2000; Murakami and Freed, 
2000). The budding virion is eventually released by membrane fission (von Schwedler et 
al., 2003). Following release, viral protease processes the Gag and Gag-Pol polyproteins 
into constituent mature Gag proteins: matrix, capsid (p24), nucleocapsid, and p6; and fully 
processed viral enzymes, protease, reverse transcriptase, and integrase (Peng et al., 1989). 
Processing of the Gag precursor induces functionally necessary structural changes within 
the virion, including the formation of the distinctive inner conical capsid core (Figure 
1.2b). 
 
HIV accessory proteins 
In addition to the structural proteins necessary for infectious virion production, HIV 
encodes four accessory proteins that mediate host immune system evasion and can 
contribute to pathogenicity of infection. 
Vif binds and directs the degradation of the cytosine deaminase APOBEC3G within 
infected cells, thereby limiting APOBEC3G’s encapsidation within newly produced 
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virions, and avoiding APOBEC3G-mediated hypermutation of proviral genomes that could 
render the virus non-infectious (Sheehy et al., 2002; Sheehy et al., 2003). 
Vpr is another virion-incorporated protein which has several functions both during 
delivery by the infecting virus particle and during post-integration viral protein production. 
Interestingly, Vpr appears to only provide a significant fitness advantage to HIV during 
macrophage infection and not in T cells. Nevertheless, Vpr and its homologs are highly 
conserved accessory proteins in all primate lentiviruses and thus have a non-dispensable 
role in vivo. Some of the many functions of Vpr that have been described include: 
promotion of nuclear importation of the pre-integration complex, G2 cell cycle arrest, and 
induction of apoptosis (Romani and Cohen, 2012). More recently, some have proposed that 
Vpr plays a role subverting the host cell DNA damage response to promote efficient 
proviral integration. Moreover, investigation of the importance of Vpr in macrophage 
infection by our lab has pointed towards a potential macrophage-specific restriction factor 
that is counteracted by Vpr and promotes efficient virus release and spread in T cell co-
cultures (Collins et al., 2015; Mashiba et al., 2014). 
Vpu is a unique accessory protein among lentiviruses whose main function is 
mediation of BST-2/tetherin degradation. As a result, Vpu Bst2/tetherin is unable to restrict 
virion release from infected cell surfaces and limit pathogenicity of infection (Neil et al., 
2008; Van Damme et al., 2008). 
Finally, Nef is a pleiotropic accessory protein that greatly increases pathogenicity 
of HIV infection. Three cellular targets of Nef are: SERINC5, cell surface CD4, and major 
histocompatibility class I (MHC-I). Nef-mediated exclusion of SERINC5 from newly 
forming virions promotes efficient subsequent infections (Usami et al., 2015) (Rosa et al., 
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2015). Downmodulation of cell surface CD4 enables HIV to avoid CD4-mediated retention 
of virions at the cell surface through interactions with virion Env protein (Lama et al., 1999; 
Ross et al., 1999). Finally, downmodulation of MHC-I prevents infected cells from CTL 
recognition and promotes infected cell survival (Collins et al., 1998). 
Regulation of HIV gene expression 
HIV proviral gene expression is exquisitely regulated by host factors as well as 
viral regulatory proteins. In a transcriptionally favorable cellular environment, HIV often 
establishes an active infection with robust viral gene expression and post-transcriptional 
replication events (Lewinski et al., 2006). Alternatively, in unfavorable cellular 
environments, proviral gene transcription can be significantly suppressed resulting in a 
latent infection and a transcriptionally dormant provirus within the host genome. 
Importantly, HIV latency can be reversed, leading to robust active viral replication (Brooks 
et al., 2001; Zack et al., 1990). The critical elements in the process of HIV gene expression 
are the viral promoter and cis-acting elements of the 5’ LTR. Binding of necessary 
transcription factors to the core promoter is sufficient to induce HIV transcription; 
however, the degree of transcription is dramatically affected by several factors and can 
dramatically change the outcome of any single infection event (Nabel and Baltimore, 
1987b; Rittner et al., 1995). Below I describe some of the important processes and factors 




 Epigenetic modifications of HIV 5’ LTR-associated nucleosomes, Nuc-0 and Nuc-
1, lead to dramatic changes in HIV transcription efficiency and regulation of HIV latency. 
Nucleosome and chromatin structure around the HIV promoter is remarkably consistent. 
Between Nuc-0 and Nuc-1 exists the nucleosome-free HIV core promoter, a scaffolding 
for the assembly of the RNA transcription machinery (Verdin et al., 1993). In an inactive 
state, the HIV core promoter is the only accessible region of the LTR to transcription 
factors due to compact or ‘closed’ chromatin structure (Demarchi et al., 1993). This state 
leads to inefficient transcription initiation and latency. Methylation and deacetylation of 
histone tails by histone methyltransferases and histone deacetylases (HDACs), 
respectively, sustains chromatin compaction and HIV latency (Blazkova et al., 2009; 
Kauder et al., 2009; Pearson et al., 2008) (Figure 1.4a). Interestingly, of the 4 classes of 
mammalian HDACs, only class 1 HDACs (HDAC1, HDAC2, and HDAC3) are recruited 
to and modulate the HIV LTR (Keedy et al., 2009). On the other hand, histone 
acetyltransferases (HATs) acetylate histone tails, promote euchromatic structure around 
the 5’ LTR and provide greater access for transcriptions factors to proviral enhancer sites 
(Steger et al., 1998; Struhl, 1996; Struhl and Moqtaderi, 1998) (Figure 1.4b and Table 
1.1). 
 
Tat-mediated transcription transactivation 
HIV transcription occurs in two phases. Early gene expression is characterized by 
relatively low levels of HIV gene products due to obstruction of RNA Pol II by negative 
elongation factor (NELF) and inefficient HIV mRNA elongation (Narita et al., 2003; 
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Yamaguchi et al., 1999; Zhang et al., 2007). Therefore, early, multiply-spliced HIV RNAs 
slowly accumulate and are translated, including those encoding for HIV Tat. Once 
produced, Tat liberates positive transcription elongation factor b (P-TEFb) from its 
inhibitory complex of HEXIM 1 and 7SK RNA and recruits P-TEFb to the transactivation-
responsive element (TAR) in nascent HIV mRNA. There, P-TEFb, phosphorylates the C-
terminal domain of stalled RNA Pol II which releases the NELF-dependent suppression 
and dramatically increases the efficiency of HIV mRNA elongation and late gene 
transcription (Kim et al., 2002; Parada and Roeder, 1996). Therefore, the Tat-TAR axis is 
composed of several proteins and whose relative abundance and activity can potently 
regulate HIV gene transcription and latency (Figure 1.5 and Table 1.1).  
 
 
Cellular factors that regulate HIV transcription 
Several cellular transcription factors bind to the HIV promoter and regulate HIV 
transcription. Below I discuss some of the most important factors necessary for 
transcription initiation and elongation. Nuclear factor kappa B (NF-κB) is a family of five 
transcription factor monomers. Three monomers contain transcription activation domains 
(p65, c-Rel, and RelB), while the other two monomers (p50 and p52) serve as transcription 
inhibitors. NF-κB transcription factors exert their effects as dimers made up of 
combinations of the five monomers (Gilmore, 2006). All dimers have the potential to 
occupy NF-κB binding motifs within the HIV 5’ LTR and the relative abundance of 
monomers determines which dimers will bind to and influence the promoter. Typically, the 
two most abundant monomers are p65 and p50 (Baldwin, 1996; Siebenlist et al., 1994). 
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Therefore, p50/p50 homodimers and p50/p65 heterodimers are the two dimers most 
responsible for HIV transcription suppression and enhancement, respectively. Often, 
cellular physiology determines the relative abundance of the uninhibited monomers 
available to bind to and affect HIV transcription. As T cell activation is associated with 
induction of NF-κB activity, activated, dividing T cells often have a greater abundance of 
p65-containing dimers available to bind to the HIV promoter (Ghosh et al., 1998; Nabel 
and Baltimore, 1987a; Thanos and Maniatis, 1995). On the other hand, quiescent T cells 
usually have relatively low levels of active p50/p65 dimers due to IκB-mediated inhibition. 
This regulation of NF-κB dimer activation involves a complex network of upstream factors 
with strict negative feedback regulation and can be affected by many diverse cellular 
stimuli (Stancovski and Baltimore, 1997). Another important HIV transcription factor is c-
Myc, which associates with SP1 proteins bound to the HIV 5’ LTR and recruits inhibitory 
HDACs to the HIV LTR (Jiang et al., 2007) (Figure 1.4, Figure 1.5, and Table 1.1). 
As described above, following transcription initiation, RNA Pol II stalls shortly 
after the transcription start site and production of long mRNA transcripts is incredibly 
inefficient. The role of P-TEFb in removing this block is critical for potent viral gene 
expression and active infection. The mechanism of P-TEFb transactivation is summarized 
above. In addition to inhibition by the hetero complex of HEXIM 1 and 7SK RNA, P-TEFb 
can be sequestered in the cytoplasm and unavailable to transactivate HIV gene expression, 
by the bromodomain protein Brd4 (Bisgrove et al., 2007; Urano et al., 2008). If in 
abundance, Brd4 competitively inhibits Tat binding and recruitment of P-TEFb to the 
nascent HIV mRNA and can promote HIV latency (Bisgrove et al., 2007; Ott et al., 2011; 
Schroder et al., 2012) (Figure 1.5 and Table 1.1). 
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Finally, heat shock protein 90 (Hsp90) is a ubiquitous cellular chaperone protein. 
Hsp90 activity is necessary for the activation of NF-κB dimers and mediates assembly of 
P-TEFb subunits (Pan et al., 2016; Zhang and Burrows, 2004). Hsp90 activity is also 
responsible for the proper folding of many other factors also involved in HIV gene 
expression, including STAT5 (Xu et al., 2003). Therefore, the activity of Hsp90 is a key 
regulator of HIV gene transcription (Table 1.1). 
 
Rev-dependent HIV mRNA nuclear export 
Incompletely spliced RNA transcripts are typically degraded within the nucleus. 
However, HIV has evolved a mechanism to avoid this fate for its incompletely spliced late 
viral gene transcripts and unspliced RNA genome. HIV Rev interacts with the Rev-
response element (RRE), a highly-conserved RNA structure contained within incompletely 
spliced HIV transcripts (Daly et al., 1989; Heaphy et al., 1990; Malim et al., 1989; Sodroski 
et al., 1986). Once bound by Rev, HIV mRNA is directed through the nuclear pore by 
canonical nuclear export processes. Thus, Rev is responsible for the nuclear export of 
incompletely processed, late HIV transcripts, which then can be translated into viral 
protein. As with the Tat-TAR axis, the Rev-RRE axis is critical for efficient active HIV 
infection and mutations to either Rev or the RRE can dramatically alter the course of 
infection (Table 1.1). 
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Persistent HIV infection and the HIV reservoir 
As discussed above, cART efficiently suppresses HIV replication in vivo but does 
not eliminate all forms of the virus as HIV replication can rebound following interruption 
of cART. Two hypotheses have been proposed to explain this phenomenon. 
 The first hypothesis to explain the persistence of HIV despite cART is that low-
level replication occurs even during therapy. It is proposed that; indeed, cART is effective 
but may not affect or reach all forms of the virus in sufficient quantity. In other words, 
there may be anatomic regions of low penetrance of antiretroviral agents where viral 
replication can occur. Evidence in support of this proposal includes: an increase of 
unintegrated HIV DNA when cART was intensified with the integrase inhibitor raltegravir, 
suggesting that new integration events were being blocked that would have otherwise gone 
on to cause new infections (Buzon et al., 2010); and evidence in several patients for residual 
plasma virus evolution, which would only be possible due to ongoing replication (Shiu et 
al., 2009; Tobin et al., 2005). Furthermore, one group, through mathematical modeling, has 
proposed that it is within lymphoid tissue where concentrations of antiretroviral drugs are 
insufficient, that ongoing, low-level HIV replication may occur (Lorenzo-Redondo et al., 
2016). However, several other groups have not been able to repeat these results (Besson et 
al., 2012; Dinoso et al., 2009; Gandhi et al., 2010; Hatano et al., 2011). Thus, it is possible 
that in some patients, some forms of HIV evade potent antiretroviral therapy and can 
replicate at very low levels; however, it cannot account for HIV persistence in every case. 
 The second hypothesis to explain the ability of HIV to persist despite cART, 
proposes that a population of long-lived cells bearing latent HIV provirus establishes a 
reservoir of transcriptionally silent HIV that can be reactivated to produce new virions even 
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decades after initial infection. Several studies have demonstrated that indeed HIV 
sequences from cART-treated, infected people do not evolve but persist (Joos et al., 2008; 
Kieffer et al., 2004; Tobin et al., 2005). Below I describe our current understanding of the 
HIV reservoir. 
 
The resting CD4+ T cell HIV reservoir 
 Activated CD4+ T cells are the most susceptible and primary cellular target of HIV. 
The cellular state of these cells; however, does not support latent HIV infection. As a result, 
most infected CD4+ T cells bear actively replicating HIV that can induce viral cytopathicity 
and produce antigen that is presented and detected by circulating anti-HIV CTLs (Ho et 
al., 1995; Wei et al., 1995). A very small proportion of activated and actively infected CD4+ 
T cells survive viral cytopathicity and immune responses and transition to a resting state, 
characterized by relative physiologic quiescence (Chun et al., 1995). It also appears that in 
some cases, HIV is able to directly infect resting CD4+ (rCD4+) T cells or CD4+ T cells in 
the process of transitioning to a resting state (Cameron et al., 2010; Chavez et al., 2015; 
Pace et al., 2012; Shan et al., 2017; Vatakis et al., 2009). In these cases, infection is 
incredibly inefficient and the likelihood of host cell death is reduced. It is within this small 
population of infected rCD4+ T cells that HIV latency is supported. 
 The contribution of rCD4+ T cells to rebound and residual viremia is currently a 
topic of great interest to the field. Because instances of treatment failure or treatment 
interruption and rebound viremia are rare, many groups look to the residual viremia that 
can be detected by ultra-sensitive laboratory assays to investigate the contribution of rCD4+ 
T cells to these circulating viral species. Interestingly, multiple studies have demonstrated 
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that residual plasma virus sequences can only infrequently be attributed to any detected 
rCD4+ T cell reservoir (Bailey et al., 2006; Brennan et al., 2009; Chun et al., 2000; Sahu 
et al., 2009; Tobin et al., 2005). It has also been discovered that the CD4+ T cell HIV 
reservoir rapidly accumulates defective proviral genomes during establishment of the 
reservoir, which is believed to be a result of frequent deleterious and inactivating 
recombination events that occur during reverse transcription (Bruner et al., 2016; Cohn et 
al., 2015). Thus, other cellular sources of persistent functional HIV may exist and also 
contribute to residual and rebound viremia. Emerging evidence suggests that macrophages 
may also form a durable reservoir of HIV (Arainga et al., 2017; Honeycutt et al., 2017). 
Although infection is incredibly inefficient in these cells, macrophages can be long-lived 
and appear to be less susceptible to viral cytopathicity compared to infected CD4+ T cells 
(Collman et al., 1989; Ho et al., 1986). 
 
Hematopoietic stem and progenitor cells as an HIV reservoir 
Following birth, all human blood cells are progeny of bone marrow-derived 
hematopoietic stem and progenitor cells (HSPCs). Hematopoiesis is a tightly regulated and 
ordered process that sustains appropriate blood cell production according to physiological 
needs for the life of an individual. Therefore, hematopoietic stem cells and even the early 
progenitor cells are long-lived (Busch et al., 2015; Sun et al., 2014). Hematopoietic stem 
cells (HSCs) are the most primitive and multipotent sub-population and have the greatest 
capacity for self-renewal. In instances where they differentiate, HSCs can produce common 
myeloid progenitors (CMPs), which give rise to the myeloid lineage of mature cells, or 
common lymphoid progenitors (CLPs), which differentiate into all lymphoid lineages of 
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mature cell (Doulatov et al., 2012). These HSCs, CMPs, and CLPs, can reliably be 
distinguished from other blood cell types based on their surface antigens CD133 and CD34. 
More committed progenitors derived from CMPs and CLPs lose surface expression of 
CD133 (Berenson et al., 1991; Leary et al., 1985; Yin et al., 1997) (Figure 1.6). 
Understanding the susceptibility of HSPCs to HIV infection in vivo has been a 
question of great interest since the start of the pandemic. Multiple studies have 
demonstrated that HSPCs do, indeed, express the cognate HIV receptor CD4 as well as the 
necessary co-receptors CCR5 and CXC4 (Alexaki and Wigdahl, 2008). Early attempts to 
determine whether HIV could infect HSPC in vivo; however, were plagued by inefficient 
cell purification methods, which could not adequately rule-out contamination by other cell 
types, including CD4+ T cells (Folks et al., 1988; Neal et al., 1995; Stanley et al., 1992; 
Zauli et al., 1992). More recently, our group sought to determine whether HIV could infect 
HSPCs using flow cytometric and PCR assays capable of single cell and single genome 
resolution. Indeed, work from our group determined that HSPCs are susceptible to HIV 
infection and could support both active and latent infection in vitro, and that HSPCs from 
about half of clinically suppressed, HIV-positive people tested contained detectable HIV 
DNA (Carter et al., 2010). Shortly thereafter, our group again demonstrated that in about 
half of HIV-positive donors tested, HSPC-derived HIV proviral DNA could be detected 
(McNamara et al., 2013). In order to assuage any concerns of T cell contamination 
confounding these results, we also described a statistical test used to demonstrate that T 
cell contamination is an extremely unlikely explanation for the detection of HIV proviral 
DNA in our HSPC samples (McNamara et al., 2013). Other groups that have also 
investigated the HSPC reservoir were unable to detect HIV DNA from HSPCs (Josefsson 
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et al., 2012; Neal et al., 1995; Shen et al., 1999; Weichold et al., 1998). Importantly, most 
of these studies recruited a relatively small cohort of donors from whom they isolated 
HSPCs. Moreover, one of these studies used flow cytometric sorting to isolate a highly 
purified population of HSPCs, but excluded CD4+ cells (Josefsson et al., 2012). Most 
recently, we demonstrated that it is the population of the CD4+ HSPCs that are most 
susceptible to HIV infection in vitro (Sebastian et al., 2017). Therefore, it is likely that 
these studies were both underpowered and experimentally flawed in order to confidently 
state that HSPCs are not a source of persistent HIV provirus in vivo. Therefore, it is 
imperative to also investigate whether HSPCs constitute a clinically-relevant, persistent 
functional HIV reservoir that contribute to residual and rebound viremia.  
Pharmacological reversal of HIV latency and elimination of the HIV reservoir 
Latent HIV infection within long-lived cellular reservoirs permits infected cells to 
survive by avoiding viral cytopathicity or immune-mediated clearance. One approach to 
promote the reduction of the viral reservoir is to reverse HIV latency, induce robust viral 
gene expression, and promote reservoir cell death (Deeks, 2012). Therefore, in addition to 
comprehensively characterizing the HIV reservoir, it has been the focus of the field to 
develop effective latency-reversing agents (LRAs) that promote the significant reduction 




Assessing LRA effectiveness 
 Definitive evidence of LRA efficacy is viral remission following cART 
interruption. Some studies have performed an analytical treatment interruption (ATI); 
however, testing and developing LRAs in vivo using ATIs is impractical and unsafe. 
Alternatively, HIV latency cell line models provide a convenient and robust system in 
which to test the efficacy of LRAs. Their relative lack of physiologic significance; 
however, has become ever-more apparent as results in cell lines have not successfully 
translated into in vivo success (Delagreverie et al., 2016; Spina et al., 2013; Spivak and 
Planelles, 2016). Quantification of proviral load reduction in vivo within HIV reservoirs 
has been proposed as another method to evaluate LRA effectiveness. Unfortunately, as 
discussed above, most proviruses within infected individuals are defective. The relevant, 
functional proviruses that would be the target of LRA-based strategies make up only about 
2-12% of HIV proviral genomes found within rCD4+ T cells (Bruner et al., 2016; Hiener 
et al., 2017; Ho et al., 2013). Therefore, even a significant reduction in the functional 
reservoir would be difficult to discern by quantification of proviral load. The gold-standard 
that has emerged for the analysis of LRA effectiveness has become the ex vivo viral 
outgrowth assay (VOA), which tests the ability of proposed chemical compounds to induce 
viral outgrowth from rCD4+ T cells from optimally-treated, HIV-infected people (Bullen 
et al., 2014; Laird et al., 2015). 
 Efficacy within rCD4+ T cells has been the main focus of LRA studies. While the 
CD4+ T cell reservoir constitutes the largest pool of persistent HIV, as I discussed above, 
additional, non-CD4+ T cells likely also contribute to the persistent HIV reservoir, 
including HSPCs. Interestingly, our group has shown that the mechanism of HIV latency 
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within HSPCs is distinct from that within CD4+ T cells and active P-TEFb is not limiting 
in in vitro, latently-infected HSPCs (McNamara et al., 2012). Moreover, unlike in latently-
infected CD4+ T cells, NF-κB activation by TNF-α was sufficient to induce latency reversal 
in HSPCs (McNamara et al., 2012). Whether additional differences in the establishment, 
maintenance, and reversal of HIV latency in HSPCs and CD4+ T cell exist is unknown. 
Therefore, proposed LRAs must also be able to reactivate latent provirus within diverse 
cell types in order to significantly reduce all forms of persistent HIV. 
 
T cell activation 
 Several classes of LRAs have been described. The earliest studies aimed at 
reversing HIV latency originated from the observation that HIV gene expression was 
correlated with T cell activation (Perelson et al., 1997; Zack et al., 1991). Therefore, two 
early clinical trials attempted to induce viral reactivation in vivo by co-treatment with anti-
CD3 antibody and interleukin-2 (IL-2). Unfortunately, these treatments led to significant 
adverse events in study participants with no obvious change in the viral reservoir 
(Kulkosky et al., 2002; Prins et al., 1999). Therefore, general T cell activation is an unsafe 
and impractical method to induce viral reactivation. Affecting distinct pathways involved 
in T cell activation; however, may provide sufficient stimuli to reverse HIV latency while 
avoiding generalized T cell activation and toxicity. Protein kinase C (PKC) agonists have 
emerged as a potentially useful LRA that promote potent NF-κB activation (Jiang and 
Dandekar, 2015). Phorbol esters, including prostratin, were the first selective PKC agonists 
to observed to reverse HIV latency, followed by bryostatin-1 (DeChristopher et al., 2012; 
Kinter et al., 1990; Kulkosky et al., 2001; Mehla et al., 2010). Both prostratin and 
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bryostatin-1 have demonstrated moderate HIV latency reversal even in ex vivo model 
system; however, supratherapeutic levels are necessary to induce potent viral reactivation 
(Bullen et al., 2014; Kulkosky et al., 2004; Laird et al., 2015; Williams et al., 2004) (Table 
1.2). Nevertheless, these proof-of-principle discoveries demonstrate that HIV latency-
reversal can be achieved without complete T cell activation. 
 
Targeting specific cellular pathways to reverse HIV latency 
 In addition to T cell activation, several screens of chemical libraries have generated 
evidence in support of LRAs that reverse HIV latency through novel mechanisms. First, 
the FDA-approved inhibitor of acetaldehyde dehydrogenase, disulfiram, was discovered to 
reactivate HIV latency in a highly-manipulated, in vitro primary CD4+ T cell model of HIV 
latency (Xing et al., 2011). Further investigation discovered that disulfiram reversed HIV 
latency by depleting cellular phosphatase and tensing homolog (PTEN), thereby activating 
the Akt-NF-κB pathway (Doyon et al., 2013). In later studies; however, disulfiram was 
shown to not be effective ex vivo or in vivo (Elliott et al., 2015; Spivak et al., 2014). Second, 
the non-canonical NF-κB pathway is involved in very few cellular processes and is further 
characterized by a relatively slow onset and prolonged transcriptional effect compared to 
the canonical pathway (Sun, 2011). The ability of non-canonical NF-κB dimers to 
transactivate HIV gene transcription is a relatively understudied topic. Nevertheless, it was 
recently demonstrated that Smac mimetics that activate the non-canonical pathway were 
able to modestly reverse HIV latency from cell lines and patient-derived cells (Pache et al., 
2015). Third, a previously underappreciated role for STAT5 in HIV latency reversal was 
discovered when benzotriazole derivatives demonstrated potent LRA activity (Bosque et 
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al., 2017). Fourth, hexamethylene bisacetamide (HMBA) and the BRD4 inhibitor JQ1 have 
been shown to reverse HIV latency in vitro by promoting P-TEFb activation (Antoni et al., 
1994; Li et al., 2013; Vlach and Pitha, 1993). Again; however, when tested in more relevant 
ex vivo models, both compounds fail to induce viral outgrowth (Bullen et al., 2014; Darcis 
et al., 2015; Laird et al., 2015). Finally, one of the previously most promising category of 
novel LRAs were the histone deacetylase inhibitors (HDIs). These epigenetic modifying 
agents, as discussed above, can potently affect histone acetylation and promote HIV 
transcription (Archin et al., 2009; Rasmussen et al., 2013; Wei et al., 2014). Moreover, the 
HDIs tested as LRAs thus far are well-characterized and have been extensively tested in 
vivo for the treatment of several malignancies (Barbarotta and Hurley, 2015; Mann et al., 
2007). Therefore, HDIs represent a clinically safe option for the reversal of HIV latency 
based on initial in vitro screens. Once again; however, the in vitro successes of the HDIs 
vorinostat, romidepsin, and panobinostat, have not translated into predictable or positive 
in vivo or even ex vivo results (Archin et al., 2012; Bullen et al., 2014; Elliott et al., 2014; 
Laird et al., 2015; Rasmussen et al., 2014; Sogaard et al., 2015). In fact, several studies 
have now shown that these HDIs are either immune-toxic or dramatically suppress CTL 
and NK cell immune function (Garrido et al., 2016; Jones et al., 2014; Pace et al., 2016). 
Thus far, the best-characterized HDIs have been those that affect more than 1 of the 4 
classes of HDAC isoforms (pan-HDI). However, as discussed above, only class 1 HDAC 
isoforms have been shown to suppress HIV gene expression. Class 1-selective HDIs have 
demonstrated modest effects in vitro, but have not been thoroughly characterized beyond 
these initial screens (Bui et al., 2017; Savarino et al., 2009; Wightman et al., 2012). 
Whether an even more selective and targeted approach to HDI-mediated HIV latency-
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reversal would be more efficient has largely been ignored in favor of ease of clinical 
translation (Table 1.2). 
 
Combinations of mechanistically distinct LRAs to achieve maximum latency reversal 
 Development of a single effective LRA may not be a practical approach to efficient 
in vivo HIV latency reversal and reservoir reduction. Therefore, combinations of 
mechanistically distinct LRAs have been the focus of many recent studies. Moreover, 
pharmacologic synergy between LRAs may promote robust latency reversal and allow for 
lower doses of drugs to be administered, which may limit significant toxicity. In the several 
studies performed using patient-derived rCD4+ T cells, investigators have focused on 
combinations of bryostatin-1 plus other mechanistically distinct LRAs (Bullen et al., 2014; 
Darcis et al., 2015; Laird et al., 2015; Martinez-Bonet et al., 2015). This is a rational 
approach given the availability of activating transcription factors that is necessary even for 
basal HIV gene transcription. Unfortunately, evidence of synergism between LRAs is 
lacking. Combinations of bryostatin-1 plus pan-HDIs or JQ1 have demonstrated additive 
effects on the amount of HIV transcription; however, no dramatic enhancement of viral 
outgrowth has been observed (Darcis et al., 2015; Laird et al., 2015). Fortunately, studies 
that assess LRA combinations are relatively recent and therefore still being developed. 
Moreover, because many of the initial LRAs identified are FDA-approved for treatment of 
other diseases, it has been possible to quickly translate modest in vitro efficacy into in vivo 
studies. Several clinical trials that test the effects of LRA combination on the in vivo HIV 
reservoir are ongoing or have just completed data collection (Delagreverie et al., 2016). 
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Summary 
HIV replication is potently suppressed in infected people by cART. Unfortunately, 
HIV can persist in these individuals even after several years of continuous cART and may 
cause relapse of viremia and HIV disease. The presence of a persistent reservoir of long-
lived, latently infected cells is a major barrier to affording a cure and improving HIV 
infection therapy. Therefore, it is necessary to better understand the HIV reservoir in vivo 
and to develop effective strategies that will reduce the persistent viral burden and lead to 
durable viral remission. 
Resting CD4+ T cells make up the largest and best-characterized reservoir of 
persistent HIV. However, not all residual and rebound plasma virus can be accounted for 
by the rCD4+ T cell reservoir. Therefore, it is highly likely that other cell types contribute 
to the total HIV reservoir in vivo. Our group has presented evidence that HSPCs are an 
additional reservoir of HIV. We have demonstrated that HSPCs are susceptible to HIV 
infection both in vitro and in vivo (Carter et al., 2010; McNamara et al., 2013; Sebastian et 
al., 2017). We have also demonstrated that HSPCs can support HIV latency in vitro that is 
uniquely susceptible to latency reversal compared to HIV latency established in rCD4+ T 
cells (McNamara et al., 2012). Finally, we have provided definitive evidence that infected 
HSPCs can maintain and propagate an integrated proviral genome to its progeny in vivo 
(Sebastian et al., 2017). The contribution of the HSPC-derived HIV reservoir to residual 
viremia; however, remains unknown. I address this point in Chapter 2. 
The failure of an effective LRA regimen is a significant limitation of the field aimed 
at discovering a strategy to reduce the viral reservoir in vivo. HDIs are attractive LRA 
candidates, especially in combinations with other compounds that promote key 
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transcription factor activation. A focus on pan-HDIs; however, may be a major oversight 
in rational LRA selection and regimen design. Extensive evidence has been presented to 
confidently conclude that only class 1 HDAC isoforms contribute to HIV latency. 
Moreover, the negative effects of pan-HDIs on immune cell viability and function is a 
critical limitation for the use of these compounds in reservoir elimination strategies. 
Whether additional negative effects are elicited by pan-HDIs on other important 
physiological processes relevant to both potent viral reactivation and elimination of HIV 
reservoirs is unknown. Therefore, I propose that class 1-selective HDIs are superior to pan-
HDIs with respect to potent viral reactivation and avoidance deleterious effects caused by 
inhibition of non-class 1 HDACs. I address these points in Chapter 3. 
Together the work presented in this dissertation represents a significant 
contribution to the HIV cure field. We describe a novel and unique long-lived reservoir of 
HIV within HSPCs. Furthermore, our discovery of the benefit of class 1-selective HDIs 
compared to pan-HDIs is an important step towards a more rational and effective HIV 
latency-reversal regimen. By these two discoveries, I hope that this work will inspire future 
studies aimed at reducing the burden of persistent HIV and achieve a cure for this 
significant human pandemic.  
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Figure 1.1. Clinical progression of untreated and treated HIV infection. Diagrammatic 
representation of the clinical course of HIV infection in terms of CD4+ T cell count (left y-
axis) and HIV plasma load (right y-axis). (a) Course of HIV infection in an untreated 
individual. (b) Course of infection in an individual treated with cART. Gray horizontal 
dashed line indicates the limit of clinical detection of plasma HIV RNA. Adapted from 




Figure 1.2. HIV genome and replication cycle. (a) Schematic of the HIV genome. (b) 
Diagram of the major steps in the HIV replication cycle. Classes of current antiretroviral 




Figure 1.3. Summary of HIV reverse transcription. Schematic representation of the 
steps of HIV reverse transcription. Dotted lines indicate molecules digested by RNaseH. 




Figure 1.4. Epigenetic regulation of the HIV promoter. The HIV 5' LTR is associated 
with two key nucleosomes, Nuc-0 and Nuc-1. (a) In a closed chromatin structure, only the 
core promoter region of the 5' LTR remains accessible to transcription factors. Often HIV 
latency is concomitant with a cellular environment that does not provide activating 
transcription factors necessary to induce basal viral gene transcription. Instead, the 
inhibitory p50/p50 homodimer occupies NF-kB binding motifs of the promoter and recruits 
HDACs that promote and maintain heterochromatic structure. Histone methylation also 
promotes 'closed' chromatin structure. (b) Activation of HIV gene expression is enhanced 
when the chromatin structure is 'open'. Shown here, the activating p65/p50 heterodimer 
binds to the NF-kB binding site within the HIV promoter and recruits HATs that promote 
histone tail acetylation and euchromatic structure. This allows for additional transcription 
factors to bind to upstream enhancer and modulatory regions on the 5' LTR, affecting basal 
HIV gene transcription.  
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Figure 1.5. Summary of mechanisms that regulate HIV gene transcription. HIV gene 
expression is regulated by several host and viral factors, some of which are summarized in 
this cartoon representation of HIV gene expression regulation. Latent, or transcriptionally 
silent, HIV provirus (left) is sustained by the activity of HDACs and a lack of activating 
cellular transcription factors. Activation of the NF-κB pathway, leads to the IKKb-
dependent release of the activating p50/p65 NF-κB heterodimer from its inhibitory IκB 
complex. Furthermore, activated and available P-TEFb is recruited to the HIV LTR by HIV 
Tat to transactivate HIV gene expression by eliminating RNA Pol II stalling soon after the 
transcription start site. The bromodomain protein, BRD4, is a competitive inhibitor of Tat 




Figure 1.6. Schematic of hematopoiesis. Hematopoietic stem cells (HSCs) are the origin 
of all blood cells in the body. In addition to their multipotent potential, HSCs also have the 
ability to self-renew. HSCs can differentiate into a common myeloid progenitor (CMP) or 
common lymphoid progenitor (CLP), which still have multipotent potential, but are 
restricted to the myeloid and lymphoid lineages, respectively. CMPs and CLPs give rise to 
additional progenitor cells that are even more committed to specific cell types. 
Hematopoietic stem and progenitor cells (HSPCs) include all cells to this stage and can be 
distinguished by their cell surface markers CD133 and CD34. More immature HSPCs, 
including HSCs, express CD133 but not CD34. Mature blood cells do not express either 
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Chapter 2  
Hematopoietic stem and progenitor cells are a unique HIV reservoir that contribute 
to persistent viremia in suppressed patients1 
Abstract 
Long-lived reservoirs of HIV are a major barrier to a cure. Thus, it is important to 
develop a better understanding of the cell types that contribute to virus production in HIV-
infected people on anti-retroviral therapy. CD4+ hematopoietic stem and progenitor cells 
(HSPCs) have the capacity for life-long survival, self-renewal, and are susceptible to HIV 
infection in vitro and in vivo. Whether HSPCs harbor infectious virus or contribute to 
plasma viremia is unknown. Here, we investigate this question in 24 optimally-treated, 
HIV-infected people. Single-genome PCR products from highly purified bone marrow-
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derived HSPCs and residual plasma virus were directly sequenced to assess the extent to 
which HSPCs harbored proviral genomes that matched plasma virus. For comparison, we 
also obtained proviral genome sequences from peripheral blood and bone marrow 
mononuclear cells. Remarkably, residual plasma virus sequences often matched clusters of 
HSPC-associated identical proviruses (CHIPs). One CHIP that matched multiple copies of 
clonal plasma virus had a deletion in the primer binding site. Loss of this element is 
predicted to allow viral transcription and virion production, but the packaged genome 
would not be competent for reverse transcription. Thus, this CHIP was likely generated by 
cellular proliferation of an infected progenitor rather than by coincidental infection of 
multiple cells by genetically similar viruses. We also found that HSPCs make an important 
contribution to plasma virus; a higher proportion of CHIPs matched residual plasma virus 
than proviral genomes from bone marrow and peripheral blood mononuclear cells that did 
not form CHIPs. Furthermore, an analysis of near full-length genomes isolated from 
HSPCs provided evidence that HSPCs can harbor functional HIV proviral genomes with 
open reading frames that often match plasma virus. These results support the conclusion 
that HIV-infected HSPCs form a distinct and functionally significant reservoir of persistent 
HIV in infected people.  
Introduction 
Combination anti-retroviral therapy (cART) efficiently blocks HIV spread in vivo. 
However, the virus is able to persist within infected individuals and rebound viremia 
frequently occurs if cART is interrupted (Davey et al., 1999). Failure of cART is thought 
to result from persistent long-lived cells that harbor integrated HIV genomes that are 
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unaffected by anti-retroviral therapy. Resting memory CD4+ T cells are a well-
characterized HIV reservoir (Chun et al., 1997; Finzi et al., 1999; Finzi et al., 1997). In 
addition, emerging data support the possibility that non-CD4+ T cells may also form a 
persistent HIV reservoir (Arainga et al., 2017; Avalos et al., 2016; Honeycutt et al., 2017; 
Zhu et al., 2002). In particular, hematopoietic stem and progenitor cells (HSPCs) are a 
long-lived cell type that has been shown to be infected in vivo and capable of propagating 
integrated provirus to CD4+ and CD4- progeny (Carter et al., 2010; Sebastian et al., 2017). 
Moreover, HSPCs are capable of producing HIV virions upon latency-reversal in vitro 
(Zaikos et al., 2018). Therefore, it is possible that HSPCs could contribute to persistent and 
rebound viremia directly or by serving as a source of infected daughter cells that can be 
activated to produce virus.  
 Residual plasma virus (PV) can be detected in treated people by ultra-sensitive 
techniques even when virus is undetectable by standard clinical tests. Sequence analysis of 
residual PV and rebounding PV in HIV-infected people indicates that virions likely come 
from the activation of latent provirus that had been archived since before the initiation of 
therapy rather than from low-level replication and spread of cART-resistant virus (Eisele 
and Siliciano, 2012; Kearney et al., 2014).  
The cellular source of residual virus remains poorly understood. A number of 
studies have shown that proviral DNA from CD4+ T cells and other peripheral blood 
mononuclear cells (PBMCs) frequently does not match residual PV (Bailey et al., 2006; 
Brennan et al., 2009; Buzon et al., 2014; Chun et al., 2000; Sahu et al., 2009). One small 
study of two donors found that virus induced ex vivo from a subset of activated T cells 
matched PV, leading the authors to conclude that it is possible that residual PV may 
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originate from a minor population of circulating CD4+ T cells (Anderson et al., 2011). 
Whether HSPCs contribute to PV is unknown. 
Genetic characterization of provirus from CD4+ T cell has demonstrated that many 
are defective and that defective proviruses rapidly accumulate (Bruner et al., 2016; Hiener 
et al., 2017; Imamichi et al., 2016). Analyses of near full-length proviral genomes indicate 
that 2-12% of CD4+ T cell-derived HIV proviral genomes have full open reading frames 
(Bruner et al., 2016; Hiener et al., 2017; Ho et al., 2013). Whether provirus from HPSCs is 
defective has not previously been examined.  
A determination that proviral genomes from HSPCs contain open reading frames 
that match plasma virus would provide evidence that HSPC-associated genomes are indeed 
functional. Here, we examine provirus and plasma virus from HSPCs and other cell types 
from a cohort of 24 donors, providing evidence in support of this conclusion. 
Results 
Single genome amplification (SGA) of proviral DNA from HSPCs and other cellular 
subsets 
Figure 2.1 depicts a summary of the donors who were recruited and included in 
this study. Of the 53 recruited donors, ten were excluded for insufficient sample size or 
suboptimal HSPC sort purity. We excluded HSPCs samples that were <80% positive for 
hematopoietic cell markers (CD133+ or CD34+) or >1% positive for CD3+ cells. In most 
cases, samples were well within our inclusion criteria with mean values of 90 - 94% 
CD133+ or CD34+ purity and mean CD3+ T cell contamination rates of 0.2 - 0.3% (Table 
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2.1). Of the 43 donors included in the study (Table 2.2), 10 contributed samples more than 
once over periods spanning 4 months to nearly 5 years.  
To determine whether HSPCs serve as a source of PV, we amplified individual HIV 
proviral genome sequences from highly purified HSPCs, HSPC-depleted bone marrow 
mononuclear cells (BMMCs), and PBMCs. For this analysis, we used a highly sensitive 
multiplex PCR protocol that was performed at limiting dilution to amplify individual 
genomes (Sebastian et al., 2017). Based on the sort purity and the frequency of HIV 
provirus in CD3+ samples, we performed a statistical analysis to determine the likelihood 
that provirus was amplified from a contaminating cell type rather than an HSPC 
(McNamara et al., 2013; Sebastian et al., 2017). Only samples that yielded HIV proviral 
DNA that was statistically not likely due to T cell contamination were included in our final 
analyses.  
Additionally, all viral sequences were compared phylogenetically to every 
previously acquired sequence and lab strain to rule out cross contamination. All included 
donor sequences clustered appropriately except for outliers which contained frameshifts.  
We determined that 25 of the 43 included donors had detectable provirus in HSPC 
DNA. Sort purity and CD3+ T cell contamination levels were very similar between the 
donors who had detectable HIV provirus in HSPC DNA and those that did not (Table 2.1). 
 
Isolation and characterization of residual plasma virus 
For each donor, we also harvested plasma from which we isolated PV. Purified 
viral RNA was converted to cDNA and HIV sequences were amplified using the multiplex 
PCR described above. We successfully detected PV from 24 out of 25 donors who had 
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provirus isolated from HSPC DNA (Figure 2.1), including donor 503501 who initiated 
cART in acute phase.  
To identify potential cellular sources of PV, we compared all PV sequences to all 
proviral DNA sequences. The total number of sequences from each source is summarized 
in Table 2.3. As expected, some of the PV matched provirus from PBMC and BMMC, a 
large percentage of which are T cells. However, phylogenetic analysis revealed that 
proviral sequences isolated from highly purified HSPCs exactly matched amplified 
residual PV in 8 of 24 donors (Figure 2.2Figure 2.9). Higher mean CD4 counts at the time 
of sampling and number of PV amplicons recovered per donor were the only clinical and 
experimental parameters which significantly differed between these 8 donors and the 16 
without matching HSPC and PV sequences (Table 2.4 and Table 2.5). 
Sequence identity across entire amplicons is suggestive that PV was derived from 
the matching proviral genome. More precisely, the likelihood that sequences identical over 
the C2-V3 env region represent identity over the entire HIV genome can be estimated at 
83% (Laskey et al., 2016). In some cases, the multiplex SGA PCR simultaneously 
generated an 828 bp fragment from the 5’ LTR into the gag open reading frame as well as 
429 bp of env C2-V3 allowing us to link two amplicons to the same genome (Figure 2.2, 
Figure 2.4, Figure 2.5, Figure 2.6, and Figure 2.8). When matching was achieved at both 
locations, the likelihood that the genomes were clonal is even higher. Thus, our findings of 
sequence identity across multiple locations within the HIV proviral genome, strongly 





Evidence that residual plasma virus is derived from clusters of HSPC-associated identical 
proviral genomes (CHIPs) 
It was relatively common in our cohort for PV to exactly match proviral sequences 
from HSPCs; across the 24 donors analyzed, when unique sequences were compared, a 
higher proportion of proviral genomes from HSPCs matched PV (9% of gag and 13% of 
env amplicons) than genomes derived from PBMC or BMMC (3% gag and 5% env; 
p<0.05; Figure 2.10a). All of the HSPC-associated proviral genome sequences that 
matched PV also matched identical clusters of proviral genomes from PBMCs or BMMCs 
(Figure 2.10b). When these matching sequences include at least four proviral amplicons 
from non-HSPC cells, we refer to them as clusters of HSPC-associated identical proviruses 
(CHIPs).  
The impact of CHIPs is apparent when comparing Figure 2.10a (unique sequences 
only) to Figure 2.10c (all sequences). Because CHIPs commonly match PV, when all 
identical copies of provirus from BMMCs and PBMCs were included in the analysis, 
significant differences observed in Figure 2.10a were lost. This result is consistent with a 
model in which latent proviral genomes in HSPCs expand and differentiate to produce 
CHIPs. Remarkably, approximately 40-50% of CHIPS could be matched to PV (Figure 
2.10b). 
 
Evidence that virions matching CHIPs are often predominant in the plasma 
Five donors, (434423, 436000, 449000, 454304, and 458311) had large groups of 
identical PV sequences that qualify as predominant plasma clones (PPCs) (Bailey et al., 
2006). For two donors, these sequences matched CHIPs (Figure 2.11). In the remaining 
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three donors, no cellular source of PPCs were identified. Thus, CHIPs account for PPCs in 
at least a subset of donors. 
 
A signature deletion found in both a CHIP and a PPC supports HSPCs as an original 
source of viremia 
While exact matches over gag and env C2-V3 regions provide strong evidence that 
genomes are clonal, it remains theoretically possible that sequence differences are present 
elsewhere in the genome. This is an important consideration as infection by genetically 
similar viruses could mimic clonality that arises by cellular proliferation and expansion of 
genetically identical viruses. We were able to exclude coincidental infection as an 
explanation in one donor (Figure 2.2). In this donor, proviral genomes from multiple 
cellular sources, including HSPCs, contained a signature deletion. This deletion, which 
likely occurred at the time of reverse transcription, eliminated the tRNA(Lys3) primer 
binding site (pbs), the dimerization initiation site and the first two packaging stem loops. 
Due to the loss of the pbs, virus generated from this proviral genome cannot initiate reverse 
transcription and is thus noninfectious (Figure 2.2a). However, the defects harbored by the 
provirus are not expected to block transcription or packaging of the RNA genome as SL3 
is sufficient for RNA genome packaging (Abbink and Berkhout, 2008). Consistent with 
this, we identified 23 clonal copies of PV harboring the deletion (Figure 2.2). The spread 
of this noninfectious provirus amongst multiple cells most likely occurred by cellular 
proliferation originating from an infected progenitor cell. Each of the infected daughter 
cells and/or the originally infected progenitor would be competent to produce noninfectious 




HSPCs harbor intact, near full-length HIV genomes 
In addition to the multiplex SGA, we sought to amplify near full-length HIV 
genomes from HSPCs of 28 donors. For this assay, we used first-round PCR primers within 
the viral LTRs and screened these products for near-full length genomes using primers that 
amplify a ~400 bp env fragment in a second-round reaction. Positive first round reactions 
were amplified with internal primers and sequenced to determine whether or not each 
individual near full-length genome was functional. In all, we identified 22 near full-length 
genomes from 10 donors (Figure 2.12). Twenty amplicons from 9 donors were statistically 
highly unlikely to have been due to T cell contamination of our HSPC samples. We 
obtained PCR products sufficient to assess the integrity of 18 HIV genomes and fully 
sequenced 9 (Figure 2.13a). Five of 18 genomes, or 28%, had open reading frames for all 
9 HIV genes (Figure 2.13b). The near full-length genomes contained intact cis elements 
(based on 3’LTR sequencing). One proviral genome from donor 409000 was missing the 
tRNA(Lys3) pbs (Figure 2.13a). 
Strikingly, of the 5 intact genomes, 3 (60%) exactly matched PV sequences as well 
as proviral genomes from PBMC and BMMC. Donor 409 produced 2 intact genomes, one 
of which had identity to a PV env amplicon (Figure 2.13a and Figure 2.6). From donor 
421, we found an HSPC-derived near full-length sequence that was also identical to a PV 
env amplicon (Figure 2.13a and Figure 2.7). Lastly, both env and gag regions from the 
near full-length genome isolated from donor 454 HSPC were identical to PV from this 
donor (Figure 2.13a and Figure 2.4). These intact genomes account for 10-14% of unique 
plasma viruses found in these donors. Moreover, sequence identify to proviral genomes 
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from PBMCs and BMMCs provides evidence that these genomes can clonally expand in 
vivo (Figure 2.13). 
 
Evidence that virions matching HSPC proviral genomes are persistently present in plasma 
Three of the 8 donors with identical PV and HSPC-derived viral sequences 
provided tissue samples on more than one occasion (435412406, 454304, 434423). For 
each of these donors, we were able to demonstrate persistent matching between PV and 
HSPC proviral genomes over time. 
Donor 435412406 contributed blood and bone marrow three times over 10 months. and we 
were able to detect unique proviral genomes in HSPCs from all three donations. Of note, a 
CHIP from the first donation matched sequences found in PV from the third donation. 
Conversely, a CHIP from the third donation was identical to PV from the first donation 
(Figure 2.3 and Table 2.4). 
Donor 454304 had been suppressed for 3.3 years at the time of the first donation 
and provided tissue again almost 4 years later. Described as donor 304000 in an earlier 
study, HSPCs from this donor’s first donation had detectable HIV provirus by a gag qPCR 
assay (McNamara et al., 2013). Using our multiplex SGA, we isolated PV from both 
donations in which the env amplicon was identical to a near full-length genome from an 
HSPC isolated from the second donation (Figure 2.2, Figure 2.6, and Table 2.4). A gag 
amplicon derived from plasma from the second donation also exactly matched this near 
full-length genome. 
Donor 434423 provided blood and bone marrow twice over 4 months. A CHIP from 
the second donation, 434, matched large clonal clusters of PV for both gag and env 
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amplicons (Figure 2.5 and Table 2.4). Among the reactions that were performed at 
limiting dilution, 2 PV PCRs produced both gag and env that were identical to HSPC-
derived gag and env amplicons (Figure 2.5a). As discussed above, the presence of identical 
gag together with env sequences in a single genome amplification reaction for both HSPC 
and PV strongly supports identity across the entire genome. These examples provide strong 
support for the conclusion that HSPC-associated genomes are functional and contribute to 
persistent residual viremia. 
Discussion 
Here, we confirm a prior studying providing evidence that HSPCs spread HIV 
proviruses by cellular proliferation (Sebastian et al., 2017) and provide new evidence that 
these clonally expanded proviruses contribute to PV. Proviral genome sequences from 
HSPCs were often identical to sequences isolated from PBMCs and BMMCs. These 
clusters of HSPC-associated identical proviruses (CHIPs) often matched PV and in two 
donors, predominant plasma viral clones exactly matched CHIP sequences. Thus, HSPCs 
and their daughter cells containing clonal genomes are capable of producing clonal virus 
that is the predominant sequence isolated from plasma.  
We also provide evidence that HSPC-associated HIV genomes are functional. A 
relatively high percentage of proviral genomes isolated from HSPCs contained complete 
open reading frames for all 9 viral genes (28%). This compares to 2-12% for CD4+ T cells 
(Bruner et al., 2016; Hiener et al., 2017; Ho et al., 2013). Remarkably, HSPC-derived near 
full-length genomes often matched plasma virus (60%). This “in vivo outgrowth assay” 
provides strong evidence that HSPCs can harbor infectious HIV. 
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The relative paucity of HSPC-derived HIV sequences compared to those of PBMCs 
and BMMCs may have led to under-sampling of the genomes harbored within HSPCs. 
Given this difference, it is even more remarkable that HSPC-associated genomes matched 
PV more frequently than unique genomes from PBMCs or BMMCS. Based on the 
frequency with which gag and env PBMC-derived amplicons matched PV sequences (3% 
and 5%, respectively), we would have expected that only 2 (gag) and 3 (env) HSPC-derived 
proviral amplicons matched PV sequences. Instead, we found 5 (gag) and 8 (env) HSPC-
derived amplicons matched PV. Based on the observed 3 (gag) and 5 (env) additional 
matching HSPC-derived amplicons and the expected proportion of matching sequences 
(3% and 5%), the probability that under-sampling overestimated that frequency of HSPC 
genomes matching PV is extremely low (3x10-5 and 6x10-6, for gag and env amplicons 
respectively). 
Determining whether genomes with identical sequences across an amplified 
segment are truly clonal can be challenging. It is theoretically possible that identical sub-
genomic proviral sequences harbored by HSPCs and other cell types were derived from 
genetically similar viruses rather than truly clonal ones. However, this is an unlikely 
explanation for our results for a number of reasons: (1) identity was observed across the 
entire variable C2-V3 env amplicon, which is associated with a clonal prediction score of 
83% (Laskey et al., 2016); (2) we were often able to exactly match both gag and env 
amplicons from the same first round SGA PCR reaction, increasing our confidence in 
clonality; (3) one CHIP that matched a PPC contained a deletion of the primer binding site 
(an 18-base pair sequence complimentary to tRNA(Lys3) that is used to prime reverse 
transcription). This defect permits viral gene expression and outgrowth; however, reverse 
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transcription in subsequent infection events cannot be primed and initiated. The most likely 
explanation for the presence of this deleted provirus in multiple cell sources is that an 
HSPC was infected by a virus that acquired this mutation during reverse transcription. The 
proviral genome then spread by cellular proliferation and differentiation. 
Loss of the tRNA binding sites sequence by a genome that is producing large 
amounts of virus raises the possibility that this genetic element could regulate viral gene 
expression. Interestingly, a number of studies have shown that transcriptional repressors 
utilize tRNA binding sites in other retroviruses to restrict viral transcription. Specifically, 
this element is required for transcriptional silencing of murine leukemia viruses (MLVs) 
that have integrated into genomes of embryonic stem cells. The repression is largely 
mediated by trans-acting factors that recognize the primer binding (Wolf et al., 2008a; 
Wolf and Goff, 2008; Wolf and Goff, 2009; Wolf et al., 2008b). Whether a related trans-
acting factor might similarly regulate HIV gene expression via the HIV tRNA binding site 
in cells with stem cell-like characteristics is not yet known. 
Clonally-expanded, HIV-infected CD4+ T cells have been described (Bruner et al., 
2016; Hiener et al., 2017; Lee et al., 2017; Maldarelli et al., 2014; Simonetti et al., 2016; 
Sun et al., 2015; Wagner et al., 2014). In prior publications, this expansion has been 
explained by insertion of the provirus into genes that regulate cell growth and/or by 
antigenic stimulation of the T cell receptor (Cohn et al., 2015; Maldarelli et al., 2014; 
Simonetti et al., 2016). Here, we provide evidence that in some cases, expansion of clonal 
HIV genomes is driven by proliferation and differentiation of an infected hematopoietic 
progenitor cell.  
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In summary, our work provides evidence that HSPCs are a functionally significant 
reservoir of persistent HIV. Proviral genomes from HSPCs are associated with expanded 
clonal HIV proviral genomes found in peripheral blood and bone marrow that contribute 
to PV. These studies shed light on how the latent reservoir is maintained in vivo and suggest 
novel therapeutic options. Selective targeting of progenitor cells or therapeutics that limit 
cellular proliferation may enhance current regimens by reducing the number of clonally 
expanded HIV proviral genomes. 
Methods 
Ethics Statement and study subjects 
HIV-infected individuals were recruited through the University of Michigan HIV-
AIDS Treatment Program and the Henry Ford Health System. Written informed consent 
was obtained according to a protocol approved by the University of Michigan Institutional 
Review Board and Henry Ford Institutional Review Board (U-M IRB number 
HUM00004959 and HFH IRB number 7403). Donors were >18 years old, with normal 
white blood cell counts and plasma viral loads were <48 copies/ml for at least 6 months on 
antiretroviral therapy. 100 ml of peripheral blood and 20 ml of bone marrow were obtained 
from each donor. All collected samples were coded and anonymized. 
 
Cell isolation and fractionation 
HSPCs were isolated from bone marrow mononuclear cells, following Ficoll-
Hypaque (GE Healthcare) density gradient centrifugation as described previously 
(Sebastian 2017). CD133+ HSPCs were positively selected, then remaining CD34+ HSPCs 
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were isolated from the first column flow through. Sort purity was ascertained by staining 
for CD133, CD34 and CD3 and flow cytometric analysis. 
 
Flow cytometry and antibodies 
Antibodies to the following human proteins were used for flow cytometry: CD133 
(phycoerythrin [PE] conjugated; Miltenyi Biotec), CD34 (conjugated with fluorescein 
isothiocyanate [FITC]; BD Bioscience), CD3 (conjugated with allophycocyanine [APC]; 
eBioscience or APC-H7-conjugated; BD Bioscience). Nonviable cells were identified and 
excluded from sorts and analyses by staining with 7-aminoactinomycin D (7-AAD) or 4,6-
Diamidino-2-phenylindole [DAPI]. Samples were analyzed using a BD FacsCanto 
cytometer. 
 
Cellular DNA isolation 
Cellular DNA was prepared using a MagNA Pure Compact System (Roche) 
according to the manufacturer’s protocol. 
 
Peripheral blood plasma HIV RNA isolation and cDNA synthesis 
Peripheral blood plasma virus was pelleted from the post Ficoll plasma fraction by 
ultracentrifugation (25,000 x g, 2 hours, 4oC). Virions were solubilized with TRIzol 
Reagent (Invitrogen) and stored at -80oC. Two micrograms of control human Raji cell line 
RNA was spiked into donor Trizol samples prior to organic extraction. The aqueous phase 
of the Trizol suspensions was purified according to the manufacturer’s protocol or with 
RNeasy Micro columns (Qiagen). RNA samples were treated with DNAse I during column 
 
68 
purification (Qiagen RNAse-free DNAse set) or after elution or resuspension with water 
(Amp Grade DNAse I, Invitrogen.) cDNA synthesis with oligo dT priming was performed 
using Superscript III First Strand cDNA Synthesis kit (Invitrogen) or qScript Flex cDNA 
Kit (Quanta Biosciences). cDNA yield was determined by real-time qRT-PCR for beta-
actin (ACTB, TaqMan Gene Expression assay ID Hs99999903_m1), with TaqMan Gene 
Expression Mastermix (Applied Biosystems) on an Applied Biosystems 7300 
thermocycler, with the following cycling conditions: 95°C for 10 minutes, then 45 cycles 
of 95°C for 15 seconds followed by 60°C for 60 seconds.  
 
Single genome PCR assay 
Cellular genomic DNA or cDNA prepared from peripheral plasma were used in a 
two-step, limiting dilution single-genome PCR. PCR was validated for single-copy 
sensitivity using ACH-2 cell DNA. Cut off for limiting dilution was 30% positive reactions. 
PBMC DNA from each donor was used to select a standard primer set that optimized HIV 
gag and env C2-V3 detection. When necessary, donor specific primers were designed for 
compatibility with standard cycling conditions described previously (Sebastian 2017). For 
near full-length (NFL) genomes, first round reactions contained primers U5-577 and a 
Dengue-tagged version of LTR-pA-R (Sebastian 2017). Second round reactions were 
performed to generate a hemi-nested second round product of approximately 9 kilobase 
pairs (kbp) and three overlapping sub-genomic regions spanning 5’ LTR/gag (~ 700 bp), 
5’ end of gag to 3’ end of env (5.3 kbp), and Vif through the poly adenylation site (3.7 
kbp). Reactions were amplified using a BioRad C1000 thermocycler. Amplicons were 
purified from agarose gel bands with the QIAQuick Gel Extraction kit (Qiagen) using 
 
69 
Machery Nagel Nucleospin columns, then sequenced directly in both directions by the 
Sanger method at the University of Michigan DNA Sequencing Core. 
While the initial PCRs from samples with higher HIV copy numbers were often not 
at limiting dilution, the frequent prevalence of identical sequences resulted in unambiguous 
consensus sequences and we included these sequences in the phylogenetic trees. For 
quantitative analyses in which we concluded that gag and env amplicons were derived from 
the same genome, only sequences from reactions performed at limiting dilution were 
included. 
 
Sequence data analyses 
Forward and reverse sequence reads were assembled into consensus sequences for 
each amplicon with SeqMan Pro. Coding regions of consensus sequences were compared 
to all previously isolated experimental sequences and HIV-1 molecular clones used in our 
lab to rule out carryover and cross-contamination. Additionally, condensed consensus 
Maximum Likelihood phylogenetic trees of all gag and env C2-V3 amplicons were 
estimated with MEGA7 (Kumar et al., 2016) for appropriate clustering. Individual donor 
phylogenetic trees were inferred by using the Maximum Likelihood method based on the 
Hasegawa-Kishino-Yano model (Hasegawa et al., 1985). Initial tree(s) for the heuristic 
search were obtained automatically by applying Neighbor-Join and BioNJ algorithms to a 
matrix of pairwise distances estimated using the Maximum Composite Likelihood (MCL) 
approach, and then selecting the topology with superior log likelihood value. A discrete 
Gamma distribution was used to model evolutionary rate differences among sites (5 
categories (+G, parameter values as noted)). Trees were drawn to scale, with branch lengths 
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measured in the number of substitutions per site. Codon positions included were 
1st+2nd+3rd+Noncoding. All positions with less than 95% site coverage were eliminated. 
 
Statistical analyses 
Fisher’s exact test to determine the probability of T cell contamination accounting 
HIV sequences found within HSPC samples was calculated as described previously 
(McNamara et al., 2013). Comparison of proportions of sequence populations was 
performed using online calculators for two-tailed Z-test comparison of 1 or 2 sample 
proportions. 
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HSPC proviral DNA: Positive Below limit of detection 
Number of donors 25 18 
Number treated since acute infection 1 1 
Male 22 16 
Female 3 2 
Black 4 4 
White 20 14 
Non-Hispanic 23 18 
CD4 count (mean) 807 710 
CD4 count (range) 215 - 2060 308 - 1183 
Viral load <20 - <50 <20 - <50 
Duration of suppression, years (mean) 4.3 3.8 
Range of suppression, years 0.5 - 13.8 0.6 - 9.2 
Mean Sort 1 purity (CD133%, CD3%) 94, 0.3 93, 0.3 
Mean Sort 2 purity (CD34%, CD3%) 91, 0.2 90, 0.2 
Mean number of cells screened (per donor) 1,020,689 683,906 
Range of cells screened 60,750 - 3,092,500 83,070 - 1,552,000 
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Table 2.2. Donor characteristics. Red, italic text indicates samples that did not meet 
criteria for purity. First 3 digits is donation number; subsequent groups of 3 digits are ID 


























409000 M/W-NH <48 1.1 853 99% 0.1% 98% 0.1% 
410000 M/W-NH <48 4.1 856 94% 0.2% 91% 0.4% 
411000 M/W-NH <48 4.2 588 95% 1.4% 94% 0.4% 
414000 M/W-NH <48 1.6 749 95% 0.2% 85% 0.3% 
415000 M/W-H <48 0.5 862 96% 0.1% 72% 0.0% 
416000 M/W-NH <48 1.1 722 97% 0.4% 93% 0.0% 
417000 M/W-NH <48 2.3 481 99% 0.0% 96% 0.0% 
418000 M/W-NH <48 8.8 671 96% 0.2% 80% 0.1% 
420000 F/W-NH <48 1.4 1315 99% 0.0% 92% 1.0% 
421000 M/W-NH <48 4.2 775 99% 0.2% 94% 0.1% 
426000 M/W-NH <40 7.1 1034 97% 0.3% 92% 0.2% 
427000 M/W-NH <48 5.3 1150 96% 0.3% 88% 0.7% 
428408 M/W-NH <48 9.2-9.6 303-444 91-95% 0.5-0.6% 86-91% 0.2-0.6% 
429000 M/W-NH <48 5.6 745 94% 0.5% 90% 0.4% 
430000 M/W-NH <40 6.4 308 98% 0.0% 94% 0.0% 
431000 M/W-NH <40 3.5 215 93% 0.2% 89% 0.2% 
432000 M/W-NH <40 5.2 565 98% 0.1% 99% 0.0% 
433407 F/B-NH <48 0.6-1.4 452-581 86-94% 0.1-2.9% 83-90% 0.2-0.5% 
434423 M/Other <48 0.9-1.2 1577-1693 92-94% 0.1-0.2% 84-89% 0.1% 
435412406 M/W-NH <48 4.7-5.5 1292-2060 95-99% 0.2-0.4% 83-99% 0.1-0.7% 
436000 F/W-NH <40 4.7 723 93% 0.9% 85% 0.3% 
437000 F/W-NH <40 1.7 418 94% 0.2% 92% 0.0% 
438000 M/W-NH <20 8.4 698 95% 0.1% 78% 0.4% 
439000 M/B-NH <20 0.8 540 96% 0.3% 93% 0.2% 
440000 M/W-NH <50 1.4 730 97% 0.4% 95% 0.2% 
441000 M/B-NH <20 2.6 618 90% 0.5% 86% 0.2% 
442000 M/B-NH <20 9.2 1112 94% 0.3% 95% 0.1% 
443000 M/B-NH <50 1.5 896 71% 1.1% 92% 0.4% 
445000 M/B-NH <20 1.1 495 87% 0.8% 89% 0.1% 
446000 M/B-NH <50 1.7 503 92% 0.5% 90% 0.2% 
447000 M/W-NH <50 0.6 544 98% 0.5% 94% 0.1% 
449000 M/W-H <20 0.6 1392 90% 0.2% 95% 0.0% 
450000 M/W-NH <40 4.3 1183 90% 0.6% 77% 0.2% 
452000 M/W-NH <40 3.1 618 86% 0.4% 70% 0.5% 
453000 M/W-NH <40 2.0 704 96% 0.8% 83% 0.2% 
454304 M/W-NH <48 3.3-7.1 533-594 92-98% 0.4% 93% 0.2% 
455312101 F/W-NH <48 2.2-6.0 812 87-99% 0.2% 83% 0.2% 
456000 M/W-NH <40 0.5 655 93% 0.8% 90% 0.3% 
457413402 M/B-NH <48 0.2-3.6 321-390 69-94% 0-0.2% 70-91% 0-0.2% 
458311 M/W-NH <48 8.2-13.0 564 85-99% 0.3% 91% 0.0% 
459419 M/W-NH <48 2.4-6.6 624 83-96% 0.0% 78-91% 0.1% 
502000 M/W-NH <40 0.7 603 84% 0.6% 74% 0.6% 
503501 M/W-NH <48 9.8-13.8 861 90-98% 0.1-0.6% 85-88% 0.1-0.4% 
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Table 2.3. Number of sequences obtained from each source of HIV. Abbreviations: 
PBMC, unfractionated peripheral blood mononuclear cells; BMMC, HSPC-depleted bone 







  Amplicons (No.) 
Sub-genomic 
region Source of DNA Total Unique* 
gag 
PBMC 622 496 
BMMC 266 240 
HSPC 58 58 
PV 201 61 
env 
PBMC 684 508 
BMMC 285 225 
HSPC 62 62 










Table 2.5. Characteristics of donors with HSPC provirus identical to plasma virus. 
Red, italic text indicates samples that did not meet criteria for purity. First 3 digits is 
donation number; subsequent groups of 3 digits are ID of previous donation(s) from the 




























409000 M/W-NH <48 1.1 853 99% 0.1% 98% 0.1% 
414000 M/W-NH <48 1.6 749 95% 0.2% 85% 0.3% 
421000 M/W-NH <48 4.2 775 99% 0.2% 94% 0.1% 
434423 M/Other <48 0.9-1.2 1577-1693 92-94% 0.1-0.2% 84-89% 0.1% 
435412406 M/W-NH <48 4.7-5.5 1292-2060 95-99% 0.2-0.4% 83-99% 0.1-0.7% 
436000 F/W-NH <40 4.7 723 93% 0.9% 85% 0.3% 
449000 M/W-H <20 0.6 1392 90% 0.2% 95% 0.0% 
454304 M/W-NH <48 3.3-7.1 533-594 92-98% 0.4-2.8% 93% 0.2% 
  Average: 3.3 1128 95% 0.3% 91% 0.2% 























411000 M/W-NH <48 4.2 588 95% 1.4% 94% 0.4% 
415000 M/W-H <48 0.5 862 96% 0.1% 72% 0.0% 
420000 F/W-NH <48 1.4 1315 99% 0.0% 92% 1.0% 
426000 M/W-NH <40 7.1 1034 97% 0.3% 92% 0.2% 
428408 M/W-NH <48 9.2-9.6 303-444 91-95% 0.5-0.6% 86-91% 0.2-0.6% 
431000 M/W-NH <40 3.5 215 93% 0.2% 89% 0.2% 
432000 M/W-NH <40 5.2 565 98% 0.1% 99% 0.0% 
437000 F/W-NH <40 1.7 418 94% 0.2% 92% 0.0% 
439000 M/B-NH <20 0.8 540 96% 0.3% 93% 0.2% 
446000 M/B-NH <50 1.7 503 92% 0.5% 90% 0.2% 
453000 M/W-NH <40 2.0 704 96% 0.8% 83% 0.2% 
456000 M/W-NH <40 0.5 655 93% 0.8% 90% 0.3% 
457413402 M/B-NH <48 0.2-3.6 321-390 69-94% 0-0.2% 70-91% 0-0.2% 
458311 M/W-NH <48 8.2-13.0 564 85-99% 0.3% 91% 0.0% 
459419 M/W-NH <48 2.4-6.6 624 83-96% 0.0% 78-91% 0.1% 
503501 M/W-NH <48 9.8-13.8 861 90-98% 0.1-0.6% 85-88% 0.1-0.4% 









Figure 2.2. Phylogenetic analysis of HIV sequences from donor 436000. (a) HIV 
genome map and identical viral sequences from indicated tissue source. Solid bars indicate 
fully-sequenced, genetically intact amplicons. Black and white hatched bars indicate the 
location of a signature deletion. The thin line connecting gag and env amplicons indicates 
sequences that originated from the same first-round reaction performed at limiting dilution. 
(b) Maximum likelihood phylogenetic trees of gag and env HIV sequences from the 
indicated tissue sources. Identical sequence groups are designated with a red bar. Identical 
sequence groups depicted in panel (a) are marked with the circled asterisk. Scale indicates 





Figure 2.3. Phylogenetic analysis of HIV sequences from donor 435412406. (a) HIV 
genome map and identical viral sequences from the indicated tissue source. Boxes indicate 
fully-sequenced, genetically intact amplicons. (b) Maximum likelihood phylogenetic trees 
of gag and env HIV sequences from indicated tissue sources. Identical sequence groups are 
designated with a red bar. Identical sequence groups depicted in panel (a) are marked with 
the circled numbers. Scale indicates nucleotide substitutions per site. Sequences from the 
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first, second, and third donations are represented by symbols that are empty, struck-





Figure 2.4. Phylogenetic analysis of HIV sequences from donor 454304. (a) HIV 
genome map and identical viral sequences from indicated tissue source. Solid bars indicate 
fully-sequenced, genetically intact amplicons. Thin line connecting gag and env amplicons 
indicate sequences that originated from the same first-round reaction performed at limiting 
dilution. (b) Maximum likelihood phylogenetic trees of gag and env HIV sequences from 
the indicated tissue sources. Identical sequence groups are designated with a red bar. 
Identical sequence groups depicted in panel (a) are marked with the circled asterisk. Scale 
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indicates nucleotide substitutions per site. Sequences from the first and second donations 





Figure 2.5. Phylogenetic analysis of HIV sequences from donor 434423. (a) HIV 
genome map and identical viral sequences from indicated tissue source. Solid bars indicate 
fully-sequenced, genetically intact amplicons. Thin lines connecting gag and env 
amplicons indicate sequences that originated from the same first-round reaction performed 
at limiting dilution. (b) Maximum likelihood phylogenetic trees of gag and env HIV 
sequences from indicated tissue sources. Identical sequence groups are designated with a 
red bar. Identical sequence groups depicted in panel (a) are marked with the circled asterisk. 
Scale indicates nucleotide substitutions per site. Sequences from the first and second 





Figure 2.6. Phylogenetic analysis of HIV sequences from donor 409000. (a) HIV 
genome map and identical viral sequences from indicated tissue source. Solid bars indicate 
fully-sequenced, genetically intact amplicons. (b) Maximum likelihood phylogenetic trees 
of gag and env HIV sequences from indicated tissue sources. Identical sequence groups are 
designated with a red bar. Identical sequence groups depicted in panel (a) are marked with 




Figure 2.7. Phylogenetic analysis of HIV sequences from donor 421000. (a) HIV 
genome map and identical viral sequences from indicated tissue source. Solid bars indicate 
fully-sequenced, genetically intact amplicons. (b) Maximum likelihood phylogenetic trees 
of gag and env HIV sequences from indicated tissue sources. Identical sequence groups are 
designated with a red bar. Identical sequence groups depicted in panel (a) are marked with 





Figure 2.8. Phylogenetic analysis of HIV sequences from donor 414000. (a) HIV 
genome map and identical viral sequences from indicated tissue source. Solid bars indicate 
fully-sequenced, genetically intact amplicons. The thin line connecting gag and env 
amplicons indicates sequences that originated from the same first-round reaction 
performed at limiting dilution. (b) Maximum likelihood phylogenetic trees of gag and env 
HIV sequences from indicated tissue sources. Identical sequence groups are designated 
with a red bar. Identical sequence groups depicted in panel (a) are marked with the circled 





Figure 2.9. Phylogenetic analysis of HIV sequences from donor 449000. (a) HIV 
genome map and identical viral sequences from indicated tissue source. Solid bars indicate 
fully-sequenced, genetically intact amplicons. (b) Maximum likelihood phylogenetic trees 
of gag and env HIV sequences from indicated tissue sources. Identical sequence groups are 
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designated with a red bar. Identical sequence groups depicted in panel (a) are marked with 





Figure 2.10. Residual plasma virus is often derived from groups of clusters of HSPC-
associated identical proviral genomes (CHIPs). (a) Proportions of unique gag and env 
proviral sequences from HSPCs, PBMCs, and BMMCs with identity to plasma virus. (b) 
Proportions of HSPC-derived gag and env sequences with sequence identity to plasma 
virus or other proviruses. CHIPs represent groups of identical proviral sequences from at 
least 1 HSPC-derived amplicon and 4 or more non-HSPC cell sources. (c) Proportions of 
HSPC, PBMC, and BMMC proviral sequences that are identical to plasma virus when all 
sequences are analyzed, including genomes with evidence of clonal expansion. Analysis 
included sequences from donors from whom we detected HIV nucleic acid in HSPCs and 
peripheral blood plasma (n=24). The number of sequences analyzed is shown in Table 2.3. 
Statistically significant differences between sample proportions were calculated by two-





Figure 2.11. Predominant plasma clones that can be attributed to a cellular source 
often match CHIPs. Bar graphs showing number of (a) gag and (b) env plasma virus 
amplicons that matched amplicons from the indicated groups of cellular proviruses from 
the five donors from whom we identified PPCs. Groups of identical plasma virus sequences 
are indicated by horizontal bars within each stacked bar graph. Groups of PPCs are 












Figure 2.13. HSPCs contain intact, near full-length HIV genomes, which are 
represented in residual plasma virus at a high rate. (a) HIV genome map and near full-
length proviral sequences from HSPCs and genetically identical sub-genomic amplicons 
from other tissue sources. All amplicons represented are from PCRs that were performed 
at limiting dilution. Donor IDs for groups of amplicons are indicated on the left. For donor 
454304, amplicons from the first and second donations are represented by empty and filled 
bars, respectively. (b) Pie graphs showing the proportion of intact, fully-sequenced near 
full-length HIV genomes from HSPCs (left) and the proportion of these intact sequences 
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Chapter 3  
Class 1-selective histone deacetylase inhibitors enhance HIV latency reversal while 
preserving the activity of HDAC isoforms necessary for maximal HIV gene 
expression2 
Summary 
Combinations of drugs that affect distinct mechanisms of HIV latency aim to 
induce robust latency reversal leading to cytopathicity and elimination of the persistent 
HIV reservoir. Thus far, attempts have focused on combinations of PKC agonists and pan-
histone deacetylase inhibitors (HDIs) despite the knowledge that HIV gene expression is 
regulated by class 1 histone deacetylases. We hypothesized that class 1-selective HDIs 
would promote more robust HIV latency reversal in combination with a PKC agonist than 
pan-HDIs because they preserve the activity of pro-viral factors regulated by non-class 1 
histone deacetylases. Here, we show that class 1-selective agents used alone or with the 
                                                 
2 This chapter has been published as: 
Zaikos TD, Painter MM, Sebastian Kettinger NT, Terry VH, and Collins KL. Class 1-selective histone 
deacetylase inhibitors enhance HIV latency reversal while preserving the activity of HDAC isoforms 
necessary for maximal HIV gene expression. 2018. Journal of Virology. 92:e02110-17. 
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PKC agonist bryostatin-1 induced more HIV protein expression per infected cell. In 
addition, the combination of entinostat plus bryostatin-1 induced viral outgrowth, whereas 
bryostatin-1- combinations with pan-HDIs did not. When class 1-selective HDIs were used 
in combination with pan-HDIs, the amount of viral protein expression and virus outgrowth 
resembled that of pan-HDIs alone, suggesting that pan-HDIs inhibit robust gene expression 
induced by class 1-selective HDIs. Consistent with this, pan-HDI-containing combinations 
reduced the activity of NF-κB and Hsp90, two cellular factors necessary for potent HIV 
protein expression, but did not significantly reduce overall cell viability. An assessment of 
viral clearance from in vitro cultures indicated that maximal protein expression induced by 
class 1-selective HDI treatment was crucial for reservoir clearance. These findings 
elucidate limitations of current approaches and provide a path towards more effective 
strategies to eliminate the HIV reservoir. 
Introduction 
Latent HIV within long-lived cells constitutes a reservoir of persistent virus that 
cannot be eliminated by antiretroviral therapy (ART) and is a major barrier to a cure (Chun 
et al., 1997; Finzi et al., 1997). Pharmacologic reversal of HIV latency has been proposed 
as a means to induce viral gene expression, rendering infected cells susceptible to viral 
cytopathic effect and immunological clearance (Deeks, 2012). Thus far, work towards this 
goal has led to the identification of mechanistically distinct drugs that affect several 
regulatory factors of HIV gene expression including histone deacetylase inhibitors (HDIs) 
and protein kinase C (PKC) agonists, such as bryostatin-1 (Archin et al., 2009; Mehla et 
al., 2010; Wei et al., 2014). Despite promising in vitro results, attempts to reduce the viral 
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reservoir in vivo using these latency reversal agents (LRAs) have failed at clinically 
achievable levels. 
 High level viral gene expression is needed for viral proteins to accumulate to toxic 
levels and kill the infected cells (Shan et al., 2012). Both HDIs and PKC agonists have the 
capacity to activate viral gene expression in patient-derived resting CD4pos (rCD4pos) T 
cells as measured by cell-associated HIV RNA, but only PKC agonists used at supra-
therapeutic levels have the capacity to induce viral gene expression sufficient for viral 
outgrowth (Bullen et al., 2014). In attempts to lower the concentrations of individual agents 
to clinically achievable levels while still maximizing viral gene expression, efforts have 
focused on combinations of HDIs and PKC agonists, which demonstrate synergistic 
induction of cell-associated HIV mRNA expression in cell line and primary cell models of 
HIV latency. However HDI combinations tested thus far have failed to maximally enhance 
gene expression as assessed by viral outgrowth assays using patient rCD4pos T cells tested 
ex vivo (Bullen et al., 2014; Laird et al., 2015) . 
 There are three main classes of histone deacetylases (HDACs) and efforts to reverse 
HIV latency have largely focused on HDIs that act on a broad range of HDAC classes (pan-
HDIs). Because broadly acting agents inhibit a wider range of HDACs, they are more likely 
to have deleterious effects that could limit maximal latency reversal. A more narrowly 
focused regimen that targets the subset of HDACs (class 1) involved in HIV latency (Keedy 
et al., 2009) may allow more efficient activation of HIV gene expression. Indeed, previous 
work has demonstrated that class 1-selective HDIs can reverse HIV latency in cell line 
models and are superior to pan-HDIs when used in combination with PKC agonists in in 
vitro primary cell HIV latency model systems (Bui et al., 2017; Savarino et al., 2009; 
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Wightman et al., 2012). These studies, however, are significantly limited by the use of 
latency models that do not fully recapitulate the effects of LRA treatment in rCD4pos T cells 
from HIV-infected people and by focusing on the frequency of reactivated proviruses 
rather than the potency of the induced viral gene expression, viral outgrowth, and clearance 
of infected cells (Bullen et al., 2014). Moreover, the efficacy of selective agents in 
hematopoietic stem and progenitor cells (HSPC),  which may constitute a small but 
important long-lived reservoir in vivo (Carter et al., 2010; Sebastian et al., 2017) has not 
been demonstrated. 
 Therefore, using an in vitro model system of HIV latency in HSPCs and rCD4pos T 
cells from optimally treated HIV-infected donors, we compared the efficacy of pan-HDIs 
to class 1-selective HDIs on viral reactivation and outgrowth from latently infected cells. 
We show that class 1-selective HDIs are unique amongst HDIs tested thus far in that they 
enhance the ability of PKC agonists to induce viral outgrowth from latently infected HSPCs 
and from rCD4pos T cells from HIV-infected people. Moreover, our results provide the first 
evidence that class 1-selective HDIs are superior at inducing viral outgrowth due to reduced 
off-target inhibition of cellular factors necessary for optimal HIV gene expression. 
Results 
A robust model of HIV latency in HSPCs allows measurement of reactivation frequency 
and viral protein production per reactivated cell 
To compare the ability of HDIs to induce HIV latency reversal we used a latency 
model system in which purified umbilical cord blood HSPCs from healthy donors were 
infected with a replication-defective, NL4-3-based HIV molecular clone that expresses 
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green fluorescent protein fused to a short Env peptide (E-GFP; NL4-3-ΔGPE-GFP; Figure 
3.1a and Figure 3.1b). Three days post-infection, actively infected (E-GFPpos) HSPCs 
were removed using fluorescence-activated cell sorting (Figure 3.1c) and the remaining 
cells, which include latently infected cells, were immediately treated with each LRA 
regimen for 24 hours. An integration inhibitor (raltegravir) was also added to block new 
integration events, ensuring that we only scored reversal of post-integration latency. 
Because latency occurs relatively frequently in the HSPC model system, the relative 
amount of viral protein production in cells bearing a reactivated provirus (E-GFPpos) could 
be accurately measured by flow cytometry via the E-GFP mean fluorescence intensity 
(MFI). 
 Consistent with our previous work (McNamara et al., 2012), when latently infected 
HSPCs were treated with TNF-α, we observed potent latency reversal compared to 0.1% 
DMSO solvent control (Figure 3.1d). The capacity to quantitatively assess the effect of 
LRAs on viral protein expression in an unmodified primary cell model of latency is a 
unique feature of our system that may allow the identification of combinations of drugs 
that will maximally reverse latency and have the greatest capacity to promote eradication 
 Based on our previous work (Painter et al., 2017), reactivation occurring in the 
solvent control is due to spontaneous differentiation of HSPCs and does not reflect latency 
reversal activity by the DMSO solvent. Compared to untreated cells, 0.1% DMSO did not 
significantly affect the frequency of E-GFPpos cells (Figure 3.1e) or the E-GFP MFI 
(Figure 3.1f).  In addition, the concentration of DMSO used in our assay was not sufficient 
to induce acetylation of histone or tubulin (Figure 3.1i). 
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 HSPCs gradually lose some expression of the CD34 cell surface marker under 
culture conditions that support HSPC proliferation. Moreover, differentiation as assessed 
by CD34 expression is associated with reactivation from latency in the HSPC model system 
(Painter et al., 2017). However, the solvent DMSO does not affect differentiation of HSPCs 
as assessed by cell surface CD34 expression (Figure 3.1g) and all cells remain lineage 
negative (Figure 3.1h). 
 
Class 1-selective HDIs induce more viral Env (E-GFP) production per infected cell than 
pan-HDIs 
 To assess the efficacy of HDIs on latency reversal in HSPCs, we performed a 
titration over a range of drug concentrations and assessed the frequency of GFPpos cells 
(Figure 3.2a) and the amount of GFP expressed per cell (E-GFP MFI, Figure 3.2b). 
Optimal concentrations were those that maximized latency reversal while minimizing 
toxicity and were consistent with results from other studies (Savarino et al., 2009; Shan et 
al., 2014; Wei et al., 2014). Work from other groups has shown that selectivity of class 1-
selective HDIs is maintained at concentrations well above those tested here (Beckers et al., 
2007; Khan et al., 2008; Lauffer et al., 2013).  Nevertheless, to confirm selectivity of HDIs 
at the concentrations chosen for our assays, we assessed their effects on histone H4 and 
tubulin acetylation. Histone H4 is deacetylated by class 1 HDACs, therefore both pan-HDIs 
and class 1-selective HDIs should promote histone H4 acetylation. In contrast, tubulin is 
deacetylated by the class 2 HDAC HDAC6 and should be affected by pan-HDIs but not 
class 1-selective HDIs. Indeed, we observed that at the concentrations chosen for our study, 
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the pan-HDI vorinostat, but not the class 1-selective HDI entinostat, inhibited deacetylation 
of tubulin, whereas both drugs inhibited deacetylation of histone H4 (Figure 3.1i).  
 A summary of results for HSPCs from at least four independent donors indicate 
that, on average, every HDI tested induced E-GFP expression in a smaller fraction of 
latently infected cells than the positive control, TNF-α (Figure 3.2c). Among HDIs, pan-
HDIs (vorinostat, panobinostat, and romidepsin) induced E-GFP expression in a 
significantly greater fraction of latently infected cells than the class 1-selective HDIs 
(entinostat, tacedinaline and mocetinostat) at the concentrations tested (Figure 3.2c).  
 In contrast, all class 1-selective HDIs tested induced significantly more viral protein 
expression per cell than pan-HDIs based on E-GFP MFI (1.5-fold, Figure 3.2d). Moreover, 
this difference in efficacy was observed across a range of concentrations; increasing the 
concentration of pan-HDIs above that used in Figure 3.2d did not overcome this limitation 
(Figure 3.2b). In addition, these differences were not due to toxicity as cell viability was 
similar at HDI concentrations chosen for our assays (Figure 3.2e) 
 We also assayed cell surface MHC-I expression in cells bearing reactivated virus, 
which has been shown to be inversely proportional to Nef expression levels (Liu et al., 
2001). We observed that treatment of latently infected HSPCs with entinostat induced an 
8-fold Nef-dependent downmodulation of MHC-I in cells bearing reactivated virus 
compared to E-GFPneg cells (Figure 3.3a). Compared to vorinostat, we observed 
significantly more downmodulation of cell surface MHC-I on cells treated with entinostat 
(1.3-fold; Figure 3.3b), which corresponds to the degree of induction of viral protein (E-
GFP) production (Figure 3.2d). Together these data demonstrate that the class 1-selective 




Pan-HDIs suppress HIV protein production induced by class 1-selective HDIs 
 The ideal LRA would maximally reverse latency in all infected cells to promote 
cytopathicity and clearance. Thus, we next asked whether combinations of pan- and class 
1-selective HDIs would maximize both frequency of cells expressing E-GFP as well as the 
amount of E-GFP expressed per infected cell. Indeed, we observed that the addition of pan-
HDIs to class 1-selective HDIs maintained the higher frequencies of E-GFPpos cells 
observed with pan-HDIs alone (Figure 3.2c). However, these combinations failed to 
achieve the high E-GFP MFIs observed with class 1-selective HDI treatment alone (Figure 
3.2d). The inhibitory effect of pan-HDIs could not be attributed to additive toxicity as there 
was no significant difference in the frequency of viable HSPCs treated with HDIs alone or 
in combination (Figure 3.2e). Based on these results, we hypothesized that the broad 
inhibitory effects of pan-HDIs had undesirable negative effects on HIV gene expression 
that did not occur with class 1-selective HDIs. 
 
Class 1-selective HDIs plus a PKC agonist maximally reactivate viral gene expression and 
pan-HDIs are inhibitory when added to these combinations 
 Reversal of HIV latency has also been observed by activating protein kinase C 
(PKC) and NF-κB using bryostatin-1. Recent studies have shown that bryostatin-1 acts 
synergistically with pan-HDIs to increase HIV cell-associated RNA transcription, but not 
viral protein production or viral outgrowth in latently infected primary CD4pos T 
lymphocytes (Laird et al., 2015; Martinez-Bonet et al., 2015; Perez et al., 2010). To 
determine whether the higher HIV protein expression observed with class 1-selective HDIs 
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could overcome limitations observed with pan-HDIs, we next investigated the effect of 
bryostatin-1 combinations. To accomplish this, we used an HIV molecular clone that 
expresses full length Gag and the human placental alkaline phosphatase (PLAP) gene 
within the HIV env open reading frame (HXB2-ΔE-PLAP; Figure 3.4a and Figure 3.4b). 
HSPCs latently infected with HXB2-ΔE-PLAP were isolated using magnetic bead sorting 
to deplete actively infected cells (PLAPpos; Figure 3.4c). We then treated PLAPneg cells 
and scored for HIV latency reversal (Figure 3.4d). 
 Using this system, we again observed that all HDIs in combination with bryostatin-
1 had similar frequencies of PLAPpos cells (Figure 3.4e). In addition, we confirmed that 
class 1-selective agents induced the highest levels of viral protein per infected cell when 
used alone, or in combination with bryostatin-1 (Figure 3.4f). 
 We next asked whether the inhibitory effect we observed with pan-HDIs on class 
1-selective HDI-mediated E-GFP expression from Figure 3.2 was also observed when 
added to combinations of bryostatin-1 plus class 1-selective HDIs in this modified latency 
model system. Indeed, when any of the pan-HDIs tested were added in combination with 
bryostatin-1 plus a class 1-selective HDI, PLAP MFI was significantly reduced in almost 
every case (Figure 3.4f). An effect that could not be attributed to additive toxicity (Figure 
3.4g). 
 
Entinostat plus bryostatin-1 maximally induces viral outgrowth and pan-HDIs are 
inhibitory when added to this combination 
 Complete HIV latency reversal is considered to be the induction of virus outgrowth 
from latently infected cells, which is needed for maximal cytopathicity. Therefore, we 
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tested the ability of LRA combinations to induce virus outgrowth from latently infected 
HSPCs. To accomplish this, we performed experiments as described in Figure 3.4 and 
assayed culture supernatants for HIV virion-associated RNA by RT-qPCR with primers 
specific for genomic HIV mRNA. Alone, HDIs induced only modest viral outgrowth, 
whereas bryostatin-1 induced more than any HDI (p < 0.01; Figure 3.5). When combined 
with bryostatin-1, entinostat significantly increased the potency of viral outgrowth 
compared to either LRA alone (Figure 3.5). When pan-HDIs were added to combinations 
of bryostatin-1 plus entinostat, we observed significant suppression of viral outgrowth, 
concordant with the suppressive effects on viral protein production described earlier 
(compare Figure 3.5 and Figure 3.4f). Importantly, latently infected HSPCs treated with 
triple-LRA combinations demonstrated neither dramatic differences in the frequencies of 
PLAPpos cells induced, nor significant cellular toxicity following treatment compared to 
relevant double combinations (Figure 3.4e Figure 3.4f). Therefore, entinostat plus 
bryostatin-1 induced the greatest viral protein production and outgrowth, which was 
suppressed by co-treatment with pan-HDIs. 
 
Entinostat plus bryostatin-1 induces maximal viral outgrowth and gene expression from 
latently infected resting CD4pos T cells from optimally-treated HIV-infected individuals 
 While previous work has demonstrated that pan-HDIs enhance the ability of 
bryostatin-1 to stimulate cell-associated RNA from patient-derived rCD4pos T cells ex vivo, 
pan-HDIs did not significantly increase bryostatin-1-induced virus outgrowth (Laird et al., 
2015). To determine whether class 1-selective HDIs could achieve this important goal, we 
treated rCD4pos T lymphocytes obtained from the donors listed in Table 3.1 with 
 
106 
bryostatin-1 alone or in combination with entinostat and assayed culture supernatants at 24 
and 48 hours for virion-associated genomic HIV mRNA. We also measured cell-associated 
HIV mRNA from cell pellets harvested at 48 hours. Remarkably, in three of four donors, 
we detected greater virus outgrowth with the combination of bryostatin-1 plus entinostat 
compared to bryostatin-1 alone (5 to 11-fold; Figure 3.6a). Concomitant with this 
increased viral outgrowth detected in the culture supernatant, we also detected more cell-
associated HIV mRNA with bryostatin-1 plus entinostat treatment compared to treatment 
with bryostatin-1 alone (Figure 3.6b). Interestingly, in the one donor from whom we did 
not detect bryostatin-1-induced virus outgrowth (419000) we nevertheless observed 
induction of cell-associated HIV mRNA with bryostatin-1 treatment as well as enhanced 
expression with the combination of bryostatin-1 plus entinostat (Figure 3.6b). 
 In both donors (412406 and 445000) from whom sufficient cells were available, we 
observed a 2 to 5-fold reduction in viral outgrowth with the addition of vorinostat to 
entinostat plus bryostatin-1 (Figure 3.6a). This was correlated with similar reductions of 
cell-associated RNA expression (Figure 3.6b). Collectively, these data suggest that even 
in ex vivo models, class 1-selective HDIs enhance bryostatin-1-mediated viral outgrowth, 
whereas pan-HDIs have an inhibitory effect that limits maximum viral gene expression and 
virion outgrowth. 
 
Entinostat plus bryostatin-1 leads to the greatest reduction of LRA-induced actively 
infected cells 
 The ultimate test of the effectiveness of an LRA is the ability to reduce the HIV 
reservoir. To compare the ability of LRAs to reduce the inducible latent viral reservoir in 
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vitro, we modified our HSPC viral outgrowth assay by washing and culturing LRA-treated 
cells an additional three days following treatment and quantified the frequency of PLAPpos 
cells that remained in culture 4 days after treatment (Figure 3.7a). We found that the 
combination of entinostat plus bryostatin-1 was the only combination that led to a 
significant reduction of infected (PLAPpos) cells based on flow cytometry (Figure 3.7b 
and Figure 3.7c). Interestingly, we observed an inverse correlation when we compared the 
frequency of residual PLAPpos cells that remained in culture 4 days after the initial LRA 
regimen treatment to the potency of latency reversal (Figure 3.7d), suggesting that more 
potent latency reversal is more likely to induce clearance of affected cellular reservoirs. 
Finally, to compare the amount of residual inducible latent HIV 4 days after initial LRA 
treatment, we treated every condition with TNF-α and quantified viral outgrowth after 24 
hours (Figure 3.7a). The only condition that lead to a significant reduction in the relative 
amount of induced viral outgrowth between the first and second treatments was bryostatin-
1 plus entinostat (Figure 3.7e). Thus, the capacity of LRAs to maximally induce virus 
release correlates with likelihood of affected cellular reservoirs being eliminated from 
culture. 
 
Vorinostat inhibits NF-κB and Hsp90 
 HDIs regulate the acetylation of many proteins, including non-histone substrates 
that can negatively affect HIV reactivation and replication (Yang and Seto, 2008). For 
example, NF-κB, which is required for HIV transcription, is known to be regulated by 
acetylation. Thus, differential effects of pan- and class 1-selective HDIs on NF-κB could, 
in part, explain the inhibitory effects of pan-HDIs (Buerki et al., 2008; Chen et al., 2002). 
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Interestingly, we found that vorinostat significantly inhibited bryostatin-1-induced NF-
κB/p65 activation in PBMCs, whereas entinostat did not (Figure 3.8a). This modest 
inhibition of bryostatin-1-mediated NF-κB/p65 activation by vorinostat is concordant with 
the suppression of viral outgrowth observed for this combination, compared to bryostatin-
1 treatment alone (Figure 3.5 and Figure 3.6). 
 Heat shock protein 90 (Hsp90) is a molecular chaperone that is required for the 
normal functioning of a number of client proteins and recent studies have demonstrated 
that Hsp90 activity is required for reversal of HIV latency (Anderson et al., 2014; Joshi et 
al., 2016; O'Keeffe et al., 2000; Pan et al., 2016; Roesch et al., 2012). Additional work has 
also shown that Hsp90 deacetylation by the class 2 HDAC, HDAC6, activates Hsp90 
activity (Bali et al., 2005; Scroggins et al., 2007) and vorinostat, which inhibits HDAC6, 
causes acetylation of Hsp90 and inhibits its function (Li et al., 2011; Muhlenberg et al., 
2009). In contrast, the class 1-selective HDI entinostat does not affect the acetylation of 
HDAC6 client proteins under the conditions of our assay (Figure 3.1i). Consistent with 
this, an acetylome analysis that compared protein acetylation by entinostat versus 
vorinostat directly demonstrated that a subset of lysine residues on Hsp90 are acetylated 
by vorinostat but not by entinostat treatment (Choudhary et al., 2009). To confirm that 
vorinostat inhibits Hsp90 activity in HIV-infected HSPCs and PBMCs, we assessed Hsp70 
levels, which are induced upon inhibition of Hsp90 activity in a heat shock factor-1-
dependent pathway (Guo et al., 2005; Isambert et al., 2015; Yong et al., 2016). As a positive 
control, we treated HSPCs and PBMCs with a specific Hsp90 inhibitor (17-AAG), which 
induced a dramatic increase in Hsp70, compared to the solvent control (Figure 3.8b and 
Figure 3.8c). In addition, we observed that vorinostat, but not entinostat, induced Hsp70 
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expression in both HSPCs and PBMCs when used in combination with bryostatin-1 
(Figure 3.8b and Figure 3.8c). Treatment with vorinostat alone also induced Hsp70 
expression in PBMCs, which was not observed with entinostat treatment (Figure 3.8c). 
Together these results provide evidence that vorinostat but not entinostat inhibits cellular 
factors necessary for robust viral gene expression and outgrowth. 
Discussion 
Multiple failed attempts to reduce the viral reservoir in vivo using pan-HDI-based 
LRA regimens emphasizes a need for a change in strategy. Shan and colleagues 
demonstrated that latency reversal regimens that induced greater viral gene expression led 
to more rapid death of infected cells by viral cytopathicity (Shan et al., 2012). Here, we 
describe effects of pan-HDIs that limit potent HIV latency reversal and provide evidence 
for a superior and effective strategy using class 1-selective HDIs. 
 We observed potent inhibition of bryostatin-1 plus entinostat-induced viral protein 
production and outgrowth by all three pan-HDIs tested. Importantly, these effects of pan-
HDIs were not due to combined toxicity of the three drugs. In fact, mocetinostat plus 
bryostatin-1 treatment was the most toxic of the LRA combinations tested and addition of 
pan-HDIs modestly increased cell viability relative to the two-LRA combination. 
Interestingly, inhibition by pan-HDIs affected protein expression and viral outgrowth but 
not the frequency of reactivated cells. As clearance in our study correlated with the amount 
of protein expressed per cell, our results highlight potential limitations of previously 
published work that only compared the frequency of proviruses affected by HDI treatment. 
While it will ultimately be important to reverse latency in all latently infected cells, it is 
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critical that reversal is sufficient to promote reservoir elimination. Thus, assays measuring 
potency of viral latency reversal within each cell are important to inform successful LRA 
regimen development. 
 In addition, we show that pan-HDIs inhibited at least two cellular factors that are 
necessary for robust viral gene expression and outgrowth (NF-κB and Hsp90). To our 
knowledge this is the first study to identify these limitations of pan-HDIs on potent latency 
reversal and clearance of infected cells. Together, with previously described negative 
effects of pan-HDIs on cytotoxic T lymphocytes and NK cells (Garrido et al., 2016; Jones 
et al., 2014; Pace et al., 2016), these results suggest that LRA regimens using pan-HDIs 
are not likely to lead to robust reservoir elimination in vivo. 
 While we describe a significant limitation of pan-HDIs in reservoir elimination 
strategies, we also provide evidence for an alternative strategy employing class 1-selective 
HDIs in combination with bryostatin-1 that maximally induce viral protein production, 
viral outgrowth, and infected cell death. The demonstration that HDI combinations can 
promote viral clearance without added cytotoxic T lymphocytes (CTLs) is important 
because we also, for the first time to our knowledge, demonstrate Nef-dependent 
downmodulation of cell-surface MHC-I on cells bearing reactivated provirus. If we 
consider CTL-mediated killing of reservoirs as the major mechanism of reservoir 
elimination, a paradoxical barrier becomes evident that the most potent latency reversal 
that promotes robust antigen production and MHC-I loading will simultaneously induce 
the greatest Nef-dependent MHC-I downmodulation and limit antigen presentation and 
CTL-killing. Robust viral gene expression is necessary for efficient CTL-mediated killing 
of reservoirs, a degree of induced viral gene expression that is not achieved by vorinostat 
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treatment alone (Shan et al., 2012). Therefore, until a specific and effective method to 
inhibit Nef-dependent MHC-I downmodulation is developed, it will be important to focus 
on latency reversal strategies that induce robust cytotoxic viral protein production and 
CTL-independent killing of reservoir cells through cytopathicity, as we show is possible in 
this study.  
 With the increasing understanding of the diversity of persistent HIV reservoirs 
(Chomont et al., 2009; Leng et al., 2014), it is important that any proposed latency reversal 
regimen affects a diverse pool of reservoir cell subtypes, despite their physiologic 
differences. Our data demonstrate that the combination of a class 1-selective HDI and a 
PKC agonist is optimal in both rCD4pos T lymphocytes and HSPCs, which, along with 
other cell types may constitute a small but important long-lived reservoir in vivo (Carter et 
al., 2010; Sebastian et al., 2017). This result is highly-encouraging especially since HIV 
latency biology in HSPCs is known to be distinct from that in rCD4pos T cells (McNamara 
et al., 2012).  
 Some assumptions and limitations of this study warrant further discussion. First, 
the selectivity of the HDIs in this study used at the indicated concentrations is an important 
assumption, but one based on many studies that investigated these HDIs for their ability to 
inhibit HDAC isoforms at various concentrations. Indeed, entinostat does not significantly 
inhibit class 2 HDACs even when used at 3-10-fold higher concentrations than used here 
(Khan et al., 2008; Lauffer et al., 2013). Nevertheless, we confirmed this selectivity in 
HSPCs at the concentrations used in our assays by demonstrating that vorinostat, but not 
entinostat, induced tubulin acetylation, which is mediated by the class 2 HDAC, HDAC6.  
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 In addition, our HIV latency model system in HSPCs demonstrates a background 
of spontaneous latency reversal in the absence of LRAs. We recently determined that this 
spontaneous latency reversal is associated with HSPC proliferation and differentiation; 
culture conditions that induce quiescence and prevented differentiation decrease viral gene 
expression (Painter et al., 2017). Moreover, undifferentiated cells expressing higher levels 
of the HSPC markers CD34 and CD133 are more likely to remain latent as compared to 
more lineage-restricted HSPCs with lower expression of HSPCs markers (Painter et al., 
2017; Sebastian et al., 2017). 
 Finally, the clearance assay described in Figure 3.7 also has some limitations as an 
alternative interpretation is that previously activated (PLAPpos) cells treated with entinostat 
plus bryostatin-1 preferentially revert to PLAPneg cells that are refractory to a second round 
of latency reversal stimulus. However, we believe this explanation is unlikely as it would 
require that entinostat plus bryostatin-1 behave in ways that have not previously been 
described to selectively suppress HIV gene transcription. Attempts to further investigate 
this possibility by quantifying proviral DNA were confounded by the presence of 
unintegrated HIV DNA present in all samples, including in the raltegravir-treated control. 
Nevertheless, the simplest and most logical conclusion based on the potency of latency 
reversal induced is that the combination of entinostat plus bryostatin-1 killed reactivated 
HIV-infected cells, clearing them from the culture more rapidly than the other treatment 
conditions because higher levels of toxic viral proteins were achieved. 
 In conclusion, while these studies identify a path towards the development of an 
effective latency reversal regimen, further studies are required to identify less toxic 
alternatives to bryostatin-1 such as recently identified bryologs that still need to be assessed 
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in clinical studies as well as other novel, more targeted approaches to latency reversal 
(Beans et al., 2013; Bosque et al., 2017). Ultimately, the identification of a more effective 
and more targeted latency reversal regimen is an important step towards the goal of 
eliminating the viral reservoir in HIV-infected people. 
Materials and Methods 
Ethics statement 
HIV-infected individuals were recruited through the University of Michigan 
HIVAIDS Treatment Program and the Henry Ford Health System. Written informed 
consent was obtained according to a protocol approved by the University of Michigan 
Institutional Review Board and Henry Ford Institutional Review Board (U-M IRB number 
HUM00004959 and HFH IRB number 7403). Donors were >18 years old, with normal 
white blood cell counts and plasma viral loads were <48 copies/ml for at least 6 months on 
antiretroviral therapy. 100 ml of peripheral blood and 20 ml of bone marrow were obtained 
from each donor. All collected samples were coded. Whole umbilical cord blood from 
uninfected donors was obtained from the New York Blood Center. All collected samples 
were anonymized. 
 
HSPC isolation and culture 
HSPCs were isolated and cultured as previously described. Briefly, mononuclear 
cells were isolated from whole umbilical cord blood by Ficoll-Paque (GE Healthcare) 
density gradient centrifugation and were frozen in BSA (7.5% in PBS; Gibco) and DMSO 
(10%; Sigma-Aldrich) or used fresh. Mononuclear cells were adherence depleted for 1-2 
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hours at 37oC in Stemspan II medium (STEMCELL Technologies). CD133pos cells were 
isolated by magnetic separation using CD133 magnetic beads according to the 
manufacturer’s protocol (Miltenyi Biotec), with the modification that 1.5 times as many 
magnetic beads were used to increase purity of sorted cells (≥ 90% CD133pos). CD133pos 
cells were cultured at 37oC with 5% CO2 in Stemspan II medium supplemented with 
CC110 cytokine cocktail (100 ng/ml stem cell factor, 100 ng/mL thrombopoietin, and 100 
ng/mL Flt3 ligand; STEMCELL Technologies) and 100 ng/mL insulin-like growth factor 
binding protein 2 (R&D Systems). 
 
Resting CD4pos (rCD4pos) T lymphocyte isolation and culture 
Peripheral blood mononuclear cells (PBMCs) of HIV-infected donors with <48 
HIV copies/mL were purified by density gradient centrifugation from whole blood samples 
as described above and frozen in FBS with 10% DMSO. Frozen PBMCs were thawed and 
washed twice by drop-wise addition of RPMI medium (Gibco) plus DNase I (Invitrogen). 
Thawed PBMCs were enriched for CD4pos T lymphocytes by negative selection using a 
CD4pos T cell isolation kit (Miltenyi Biotec). CD4pos T lymphocytes were further enriched 
for resting CD4pos T lymphocytes by magnetic bead depletion of cells that expressed CD69, 
CD25, or HLA-DR (CD69 MicroBead Kit II, CD25 MicroBeads, and HLA-DR 
MicroBeads, Miltenyi Biotec). Purity of rCD4pos T lymphocytes was assessed by flow 
cytometry and was greater than 90%. Cells were immediately used in viral outgrowth 
assays in which rCD4pos T lymphocytes were cultured in T cell culture medium (RPMI 
supplemented with 10% FBS, 20 mM HEPES (Invitrogen), 100 U/mL penicillin, 100 




Virus constructs and infection of HSPCs 
NL4-3-ΔGPEN-E-GFP (ΔGPEN) was generated by disrupting Nef expression 
from NL4-3-ΔGPE-E-GFP (ΔGPE) (McNamara et al., 2012) by Xho1 digestion followed 
by Klenow polymerase fill-in and re-ligation. Generation of HXB2-ΔE-PLAP has been 
previously described (Chen et al., 1996). Infectious supernatants were prepared by 
transfection of proviral plasmids into 293T cells (ATCC) using polyethylenimine. Proviral 
plasmids were co-transfected with plasmid encoding the vesicular stomatitis virus 
glycoprotein (VSV-G). For plasmids that lacked HIV structural genes (ΔGPE and 
ΔGPEN), a helper plasmid (pCMV-HIV) was also co-transfected to provide necessary 
structural proteins in trans and permit infectious particle formation. 48 to 72 hours after 
transfection, culture supernatants were harvested and filtered through a 0.45 µm syringe 
filter (GE Healthcare). 293T cells were cultured in Dulbecco’s modified Eagle medium 
(DMEM; Gibco) supplemented with 10% fetal bovine serum (FBS; Gibco), PSG, and 5.6 
µg/mL plasmocin (Invivogen). HSPCs were infected by spin inoculation at 1,049 x g for 2 
hours at room temperature. Mock infected controls were treated with 293T cell culture 
medium. Following spin infection, viral supernatant was removed and cells were cultured 
in STIF medium for 3 days. 
 
Sorting infected HSPCs 
HSPCs infected with ΔGPE or ΔGPEN viruses were sorted by fluorescence-
activated cell sorting (FACS) using a FACSAria III (BD Biosciences) flow cytometer to 
remove E-GFPpos (actively infected) cells and enrich for E-GFPneg (latently and uninfected) 
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cells. Gating was determined based on mock infected control. HSPCs infected with HXB2-
ΔE-PLAP were sorted using magnetic beads to isolate PLAPneg cells. Briefly, infected 
HSPC cultures were incubated on ice in magnetic-activated cell sorting (MACS) buffer 
(PBS, 0.5% BSA, and 2mM EDTA) for 20 minutes with FcR blocking reagent (Miltenyi 
Biotec) and biotinylated antibody raised against PLAP (Serotec). Cells were washed with 
MACS buffer and then incubated at 4oC for 15 minutes in MACS buffer with streptavidin-
conjugated magnetic beads (Miltenyi Biotec). Cells were washed, placed on a magnetic 
column, and cells that did not bind to the column (PLAPneg) were collected. Column-bound 
cells were also collected by elution with 5 mL of MACS buffer and used to check sort 
efficiencies. 
 
Treatment of sorted E-GFPneg HSPCs 
Sorted, E-GFPneg cells (50,000-80,000 cells) were incubated for 24 hours at 37oC 
with 5% CO2 in 200 µL of Stemspan II medium plus 8 µM raltegravir (Selleck Chemicals) 
with the following drugs and controls: 0.1%[v/v] DMSO (Sigma-Aldrich), 3 ng/mL tumor 
necrosis factor alpha (TNF-α; R&D Chemicals), 1 µM vorinostat (Cayman Chemical or 
Selleck Chemicals), 25 nM panobinostat (Selleck Chemicals), 25 nM romidepsin (Selleck 
Chemicals), 10 µM entinostat (Cayman Chemical or Selleck Chemicals), 10 µM 
tacedinaline (Selleck Chemicals), 10 µM mocetinostat (Selleck Chemicals). Unless 
otherwise indicated, concentrations of drugs remained the same in all experimental 




Treatment of sorted PLAPneg HSPCs 
Sorted, PLAPneg cells (250,000-750,000 cells) were incubated for 24 hours at 37oC 
with 5% CO2 in 1 mL of Stemspan II medium plus 8 µM raltegravir and with the following 
drugs and controls: 0.1%[v/v] DMSO, 3 ng/mL TNF-α, 1 µM vorinostat, 25 nM 
panobinostat, 25 nM romidepsin, 10 µM entinostat, 10 µM tacedinaline, 10 µM 
mocetinostat, 5 nM bryostatin-1 (Sigma-Aldrich). Unless otherwise indicated, 
concentrations of drugs remained the same in all experimental conditions, including for 
those testing drug combinations. 
 For experiments presented in Figure 3.7, sorted, PLAPneg cells (800,000-1,000,000 
cells) were incubated at 37oC with 5% CO2 in 1 mL of Stemspan II medium plus 8 µM 
raltegravir and with the indicated drugs at the concentrations described above. After 24 
hours, supernatants were harvested as described below, 10% of cells were collected and 
stained for flow cytometric analysis, and the rest of the cells were washed once in PBS 
before being plated in STIF medium (1 mL) and cultured without stimulus for 3 days. After 
3 days in culture, 10% of cells were again collected from each sample and stained for flow 
cytometric analysis. The rest of the cells were re-plated in Stemspan 2 medium with 
raltegravir and TNF-α at the concentrations described above. After 24 hours, supernatants 
were harvested and cells were collected and stained for flow analysis. 
 
Treatment of rCD4pos T lymphocytes 
Five million rCD4pos T lymphocytes were incubated for 24 and 48 hours in 1 mL 
of T cell culture medium with the indicated drugs at the following concentrations: 50 
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ng/mL PMA (Sigma-Aldrich), 1 µM ionomycin (Sigma-Aldrich), 5 nM bryostatin-1, 10 
µM entinostat, 1 µM vorinostat.  
 
Measurement of MHC-I downmodulation on treated E-GFPneg HSPCs 
E-GFPneg HSPCs from ΔGPE or ΔGPEN infected cultures were isolated by FACS, 
treated with indicated drugs for 24 hours, and stained for flow analysis. Fold 
downmodulation of cell surface MHC-I on infected cells was determined by dividing the 
median fluorescence intensity (MedFI) of the surface MHC-I stain for E-GFPneg cells by 
that of the E-GFPpos cells for each condition. 
 
Measurement of supernatant HIV mRNA from treated PLAPneg HSPC cultures 
Culture supernatants were harvested at 24 hours after addition of drugs and cell 
debris was removed by centrifugation (700 x g; 5 minutes; 4oC). Supernatant RNA was 
extracted from clarified supernatant with TRIzol LS reagent according to the 
manufacturer’s protocol (Invitrogen). cDNA synthesis was performed using qScript cDNA 
Supermix (Quanta Biosciences). Real-time qPCR was performed using TaqMan Gene 
Expression Mastermix (Applied Biosystems) on an Applied Biosystems 7300 
thermocycler, with the following cycling conditions: 95°C for 10 minutes, then 45 cycles 
of 95°C for 15 seconds followed by 60°C for 60 seconds. Primers and probes have been 
previously described (Bullen et al., 2014). Molecular standard curve was generated as 




Measurement of supernatant HIV mRNA from treated rCD4pos T lymphocyte cultures 
Culture supernatants were harvested at 24 and 48 hours after addition of drugs and 
cell debris was removed by centrifugation. Supernatant RNA was extracted from clarified 
supernatant with Trizol LS reagent according to the manufacturer’s protocol. cDNA was 
synthesized and real-time qPCR was performed as described above with the modification 
that TaqMan Fast Advanced Mastermix (Applied Biosystems) was used for real-time 
qPCR.  
 
Measurement of cell-associated HIV mRNA from treated rCD4pos T lymphocytes 
Cell-associated HIV RNA transcripts were measured as previously described 
(Laird et al., 2015). Briefly, cell-associated RNA was extracted from treated rCD4pos T 
lymphocytes cells with TRIzol reagent according to the manufacturer’s protocol. 
Contaminating genomic DNA was removed by DNase I digest (Invitrogen). cDNA 
synthesis was performed using qScript cDNA Supermix. Real-time qPCR was performed 
using TaqMan Fast Advanced Mastermix on an Applied Biosystems 7300 thermocycler. 
Levels of RNA polymerase II (PolR2A) were measured for each sample as a control. 
Molecular standard curves for HIV mRNA were generated as described above. 
 
NF-κB/p65 Binding ELISA 
Whole cell lysates from treated PBMCs were obtained using a commercial kit 
according to the manufacturer’s protocol (Active Motif). Total protein amounts of lysates 
were quantified by Bradford assay (Thermo Fisher) and an equal total protein amount was 
loaded for each sample in subsequent assays. The activated form of the NF-κB monomer 
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1-3 million HSPCs or PBMCs were treated with the indicated drugs for 24 hours 
and lysed with Laemmli lysis buffer. Proteins from whole cell lysates were separated by 
gel electrophoresis, transferred to a membrane and detected using antibodies against Hsp70 
(Enzo Life Science), Hsp90 (Abcam), and GAPDH (Sigma-Aldrich). 
Acetylated histone H4 and tubulin immunoblot 
500,000 HSPCs were treated with the indicated drugs for 9 hours and lysed with 
Laemmli lysis buffer. Proteins from whole cell lysates were separated by gel 
electrophoresis, transferred to a membrane and detected using antibodies against acetylated 
alpha-tubulin (Sigma-Aldrich), acetylated histone-H4(Lys12) (Millipore), and GAPDH 
(Sigma-Aldrich). 
 
Flow cytometry antibodies and staining 
Antibodies raised against the following antigens were used for flow cytometry: 
CD133 (phycoerythrin (PE) conjugated; Miltenyi Biotec), CD34 (fluorescein 
isothiocyanate[FITC] conjugated, allophycocyanin (APC) conjugated, and PE-Cy7 
conjugated; all from Miltenyi Biotec), hematopoietic lineage markers (eBioscience), 
MHC-I (clone Bw4 and Bw6, PE-Cy7-conjugated; Miltenyi Biotec), PLAP (eFluor660-
conjugated, eBioscience), and HIV Gag (clone KC57, FITC- or PE-conjugated; Beckman 
Coulter). Flow data were collected with a BD FACS Canto cytometer or a BD FACScan 
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cytometer with Cytek 6-color upgrade. For staining of surface proteins, cells were 
suspended in FACS buffer (PBS with 2% FBS, 1% human serum, 2mM HEPES, and 
0.025% sodium azide) and antibodies, incubated on ice for 10 minutes (CD34, CD133) or 
30 minutes (MHC-I and PLAP), washed, and then fixed in 2% paraformaldehyde in PBS. 
Intracellular HIV Gag was stained by permeabilizing fixed cells with 0.1% Triton X-100 
in PBS for 5 minutes at room temperature, then incubating in FACS buffer with antibody 
against HIV Gag for 30 minutes at room temperature, and washing before analyzing. 
Statistics 
Statistical analyses were performed using Microsoft Excel software. The statistical 
tests used to calculate p-values are indicated in the corresponding figure legend. 
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Table 3.1. HIV-infected donor characteristics. 
  
Donor ID Age Sex Race 
Year of 




Duration of viral 
suppression 
(months) 
412406 45 M W 2007 3TC, AZT, EFV 62 60 
419000 53 M W 1986 FTC, TDF, ATV/r 192 28 
445000 59 M B 2009 FTC, TDF, EFV 32 13 
457413402 50 M B 2011 FTC, TDF, EFV 59 55 
M, male; F, female; W, white; B, black; 3TC, lamivudine; AZT, zidovudine; ATV/r, atazanivir boosted with 




Figure 3.1. Model system of HIV latency in HSPCs. (a) Schematic illustration of HIV 
activation assay in HSPCs. (b) Schematic diagram of NL4-3-based HIV molecular clone 
used for activation studies. Filled black and green rectangles indicate genes that have been 
deleted from or added to the wild-type molecular clone, respectively. (c) Flow cytometric 
analysis of mock infected and sorted, infected HSPCs used for activation studies. Numbers 
above gates indicate the frequency of live E-GFPpos cells. Live cells were gated based on 
FSC and SSC parameters. (d) Representative flow cytometric analysis of infected HSPCs 
treated for 24 hours with the indicated LRAs. Live cells were gated based on FSC, SSC, 
and 7-AAD. Numbers above gates indicate the frequency of CD34pos, E-GFPpos cells. 
Italicized numbers in brackets indicate E-GFP MFI of cells within the gate. Gates are based 
on mock infected cells and staining with an isotype control antibody. Summary graphs 
showing the frequency of (e) E-GFPpos cells, (f) E-GFP MFI, and (g) frequency of CD34pos 
HSPCs following 24 hour treatment with medium and 0.1% (v/v) DMSO. (h) Flow 
cytometric analysis of HSPCs and PBMCs for cell surface CD34 and lineage markers. (i) 
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Immunoblot analysis of whole cell lysates from HSPCs treated for 9 hours with indicated 





Figure 3.2. HDI combinations reveal an inhibitory effect of pan-HDIs that limits HIV 
protein production in HSPCs. Summary graphs of (a) frequency of E-GFPpos, CD34pos 
HSPCs and (b) E-GFP MFI in CD34pos cells bearing activated HIV following 24 hour 
treatment over the range of HDI concentrations indicated (mean ± s.e.m., n = 3). (c) 
Summary graph of the frequency of E-GFPpos, CD34pos cells following treatment with 
the indicated LRAs at the concentrations described in Materials and Methods and used in 
all subsequent assays. The frequency of spontaneous reactivation observed in DMSO 
solvent conditions was subtracted from each experiment to reflect the actual frequency of 
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reactivated provirus. Each symbol represents data from an independent experiment (mean 
± s.e.m., n ≥ 4). (d) Summary graph of E-GFP MFI in E-GFPpos, CD34pos cells (mean ± 
s.e.m., n ≥ 4). (e) Summary graph of frequency of viable HSPCs following 24 hour 
treatment with HDIs alone and in combinations at the concentrations used for HIV latency-
reversal studies. Cell viability was calculated using percentage of cells within live cell 
gating strategy based on FSC, SSC, and 7-AAD. Data are presented as a percentage of the 
effect of TNF-α. P values were calculated by two-tailed, unpaired Student’s t-test. *p < 
0.05, ****p < 0.0001. Solid bars indicate statistically significant differences between 
groups of conditions. 




Figure 3.3. Entinostat induces more Nef-dependent downmodulation of MHC-I than 
pan-HDIs. (a) Representative flow cytometric analysis of MHC-I downmodulation on 
latently infected HSPCs treated with the indicated LRAs. The magnitude of MHC-I 
downmodulation in HSPCs with induced viral gene expression was calculated by dividing 
the MHC-I median fluorescence intensity (MedFI) of the E-GFPneg population by that of 
the E-GFPpos population for each sample (E-GFPnegMHC-I MedFI / E-GFPposMHC-I MedFI). (b) 
Summary graph of fold MHC-I downmodulation. Data are presented relative to DMSO 
(mean ± s.e.m., n ≥ 4). Class 1-selective HDIs are shown in red and pan-HDIs are shown 
in green and blue. P values were calculated by two-tailed, unpaired Student’s t-test. *p < 
0.05, ***p < 0.001. Asterisks above each condition indicates statistically significant 
difference compared to DMSO. Solid bar indicates statistically significant differences 





Figure 3.4. Class 1-selective HDIs plus bryostatin-1 maximally induce latency-
reversal and viral protein production, whereas pan-HDIs are inhibitory when added 
to these combinations. (a) Schematic illustration of modified HIV latency-reversal model 
system in HSPCs. (b) Schematic diagram of HXB2-based HIV molecular clone. Filled 
black and green rectangles indicate genes that have been deleted from or added to the wild-
type molecular clone, respectively. Filled gray rectangles indicate genes that are 
dysfunctional in the wild-type HXB2 molecular clone. (c) Flow cytometric analysis of 
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mock infected and sorted, infected HSPCs. Numbers above gates indicate the frequency of 
live PLAPpos cells. Live cells were gated based on FSC and SSC parameters. (d) 
Representative flow cytometric analysis of infected HSPCs treated for 24 hours with the 
indicated LRAs. Live cells were gated based on FSC and SSC. Numbers above gates 
indicate the frequency of PLAPpos, Gagpos cells. Italicized numbers in brackets indicate 
PLAP MFI of cells within the double-positive gate. Gates are based on mock infected cells 
and staining with an isotype control antibody. Summary graphs of (e) frequency of 
PLAPpos, Gagpos cells; (f) PLAP MFI of PLAPpos, Gagpos cells; and (g) relative cell viability 
following treatment with the indicated LRAs. The frequency of spontaneous reactivation 
observed in DMSO solvent conditions was subtracted from each experiment to reflect the 
actual frequency of reactivated provirus. Data are presented as a percentage of the effect 
of TNF-α (mean ± s.e.m., n ≥ 3). P values were calculated by two-tailed, unpaired Student’s 





Figure 3.5. Entinostat plus bryostatin-1 induces maximum viral outgrowth from 
latently infected cells, whereas pan-HDIs are inhibitory when added in combination. 
Summary graph of genomic HIV mRNA copies/mL measured in supernatants from 
cultures of latently infected HSPCs treated as described in Figure 3.4. Data are presented 
as a percentage of the effect of TNF-α (mean ± s.e.m., n ≥ 4). P values were calculated by 





Figure 3.6. Entinostat plus bryostatin-1 induces maximum viral outgrowth and gene 
expression in latently infected rCD4pos T cells from HIV-infected individuals. (a) 
Graphical analysis of HIV released by patient rCD4pos T cells following treatment with 
indicated LRAs (mean ± s.d. of experimental duplicates). Limit of quantification is 
indicated by dotted gray horizontal line in panel. (b) Induced cell-associated HIV mRNA 






Figure 3.7. Potency of latency-reversal is correlated with survival of affected cells 
bearing reactivated HIV. (a) Schematic of in vitro assay to test the survival of latently-
infected HSPCs following treatment with LRAs (b) Representative flow cytometric 
analysis of HSPCs 1 and 4 days after treatment with LRAs. (c) Summary graph showing 
the relative frequency of residual PLAPpos cells in culture four days post-LRA treatment. 
(d) Summary graph showing inverse correlation between frequency of residual infected 
cells on 4 days after LRA treatment and potency of induced viral outgrowth by the 
indicated LRAs. Data were fit to a least-squares nonlinear regression. (e) Box and whisker 
plot (5-95 percentiles) of virus released into culture supernatant by HSPCs treated with 
TNF-α four days after initial LRA treatment. To facilitate comparison across multiple 
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experiments, data were normalized to TNF-α, n=5). P values were calculated by two-tailed, 





Figure 3.8. Vorinostat inhibits cellular factors important for robust HIV gene 
expression. (a) Summary graph showing abundance of activated NF-κB/p65 in PBMCs 
treated for 24 hours with indicated LRAs. Data were normalized to the effect bryostatin-1 
(mean ± s.e.m., n ≥ 4). Immunoblot analysis of whole cell lysates from HSPCs (b) and 
PBMCs (c) treated for 24 hours with indicated LRAs. P values were calculated by two-
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Chapter 4  
Discussion 
Durable remission of HIV disease without the need for antiretroviral therapy is an 
unattained objective for HIV cure research. The establishment of a persistent, latently-
infected HIV reservoir of long-lived cells remains the greatest barrier to achieving this 
goal. Therefore, it is imperative to better understand and characterize the HIV reservoir 
and develop strategies to eliminate sources of persistent virus. 
Work, thus far, on understanding the HIV reservoir has focused on the contribution 
of rCD4+ T cells; however, evidence suggests that non-CD4+ T cell reservoirs also exist. 
Previously, our group demonstrated that HSPCs are persistently infected in optimally-
treated, HIV-infected people (Carter et al., 2011; McNamara et al., 2013; Sebastian et al., 
2017). In chapter 2, I described our recent evidence demonstrating that HIV-infected 
HSPCs contribute to residual viremia in HIV-infected individuals. Furthermore, we 
provide evidence that large clusters of HSPC-associated identical [HIV] proviruses 
(CHIPs) from PBMCs, CD4+ T cells, and BMMCs, may arise due to differentiation of an 
originally infected HSPCs. We also demonstrate that the HSPC reservoir of HIV provirus 
is uniquely functional and CHIPs are often genetically identical to predominant plasma 
virus sequences. 
Potent HIV latency reversal aims to promote the reduction of the viral reservoir. 




recently published work that demonstrates that class 1-selective HDIs can act additively 
with the PKC agonist bryostatin-1 to potently induce HIV reactivation in both latently-
infected HSPC and rCD4+ T cells from optimally-treated individuals. Furthermore, we 
provide evidence that while pan-HDIs can reactivate latent HIV, they suppress robust viral 
gene expression, in part, due to their inhibitory effects on the pro-viral cellular factors NF-
κB and Hsp90. Finally, we demonstrate that the potent LRA combination of bryostatin-1 
plus the class 1-selective HDI entinostat also promotes a dramatic elimination of latently-
infected cells in vitro, whereas less potent, pan-HDI-containing combinations do not. 
Together, these findings provide a more comprehensive understanding of HIV 
reservoir targets and strategies with which to eliminate persistent viral reservoirs. In this 
chapter, I will outline and discuss the significance of our findings within the current body 
of literature and describe future directions that can address the exciting new questions that 
are raised by our discoveries. 
The HIV reservoir 
A relatively high proportion of HSPC-derived HIV proviruses are functional 
In chapter 2, I described our work to characterize the HIV reservoir within HSPCs 
from 43 treated, HIV-infected individuals who had clinically undetectable viremia for at 
least 6 months. From 13 of these donors, we were able to detect and fully analyze 18 HSPC-
derived near full-length HIV proviral genomes. A surprisingly large proportion of these 
near full-length genomes were determined to contain intact open reading frames for all 9 
viral genes and are likely replication-competent proviruses (5 of 18; 28%). Compared to 




appears that the HSPC-derived HIV reservoir may bear a greater proportion of replication 
competent and physiologically relevant proviruses (Bruner et al., 2016; Hiener et al., 2017; 
Ho et al., 2013). Importantly, no study that has investigated near full-length HIV proviral 
genomes, including ours, is methodologically directly comparable. Ho et al. initially asked 
whether HIV proviruses that could not be reactivated ex vivo contained functional genomes 
that would be capable of virus outgrowth. Therefore, the CD4+ T cells from which their 
near full-length proviral genomes were derived had been extensively manipulated, 
including treatment with T cell activating stimuli and prolonged in vitro culture. Moreover, 
Ho et al. only fully analyzed near full-length sequences that had been positive by their 
initial screen for a gag sub-genomic fragment. This may have led to an overestimation of 
the frequency of intact genomes due to the omission of amplicons that were gag-negative 
and likely non-functional by their initial screen. Of the three studies conducted using 
patient-derived CD4+ T cells, the estimated size of the functional HIV reservoir within 
CD4+ T cells proposed by Ho et al. is the greatest and most discordant (12%). The other 
two studies that also estimated the size of the functional CD4+ T cell reservoir used more 
unbiased methods to analyze their samples and report proportions that are much more 
concordant (2% and 5%) (Bruner et al., 2016; Hiener et al., 2017). Because we initially 
screened all near full-length first round PCR products with primers that amplify a sub-
genomic fragment of HIV env, we may also be overestimating the proportion of intact 
HSPC-derived HIV proviruses; however, our samples were neither cultured nor exposed 
to any stimuli beyond those experienced during magnetic sorting, unlike cells analyzed by 




 A study to compare the frequencies of intact near full-length genomes in multiple 
cell types from a large cohort of optimally-treated individuals has been proposed by our 
group. By performing all assays in exactly the same manner for samples of different viral 
sources, this work will permit the most direct comparison of the frequencies of intact near 
full-length proviruses from HSPCs, PBMCs, and CD4+ T cells. 
 
HIV-infected HSPCs contribute to residual plasma viremia 
We also found that HSPC-derived provirus exactly matched plasma virus 
sequences in one third of the donors from whom we isolated both sources of virus. We 
discovered that HSPC-derived proviral sequences were about 3-fold more represented 
within plasma virus sequences compared to PBMC- or BMMC-derived proviral sequences. 
Previous studies examining the CD4+ T cell proviral reservoir have consistently reported 
that these proviral sequences are underrepresented within residual plasma virus sequences 
(Bailey et al., 2006; Brennan et al., 2009; Chun et al., 2000). Moreover, others also 
demonstrated that CD4+ T cell-derived provirus and plasma virus sequences were, in fact, 
genetically compartmentalized (Sahu et al., 2009; Sahu et al., 2010).  
Whether HSPCs can contribute directly to residual and rebound viremia by viral 
outgrowth is an intriguing question. In vitro stimulation of myeloid differentiation of 
patient-derived HSPCs has been shown to induce intracellular HIV Gag expression and 
lead to rapid cell death (Carter et al., 2010). Therefore, differentiating HIV-infected HSPCs 
may reactivate latent provirus, produce new infectious virions, and lead to cell death 
(Figure 4.1). Using stimuli that do not promote HSPC differentiation, we have failed to 




HSPCs. Based on our data in rCD4+ T cells from optimally-treated people and in in vitro 
latently-infected HSPCs, it is unlikely that our stimuli were insufficient to induce latency 
reversal in HSPCs. Instead, it is more likely that our HSPC ex vivo viral outgrowth assays 
used far too few cells to have any reasonable level of confidence that an intact and inducible 
provirus was present in our pool of treated cells. Based on the rate of detected HIV infection 
of HSPCs in vivo, the frequency of predicted intact/functional HSPC-derived proviral 
genomes, and the frequency of rCD4+ T cell-derived proviruses that are inducible by a 
single activating treatment (Ho et al., 2013), we estimate that over 60 million patient-
derived HSPCs would need to be treated to have a 95% chance of detecting a single 
inducible, replication-competent provirus. Our current study design is unable to provide 
such a large number of HSPCs even if pooled from several donors. That is why future 
directions include modification of our study design to harvest larger volumes of bone 
marrow tissue and investigation of SIV ex vivo viral outgrowth from HSPCs obtained 
during necropsy of SIV-infected, cART-treated rhesus macaques. 
Additionally, given the lack of evidence for a clonal HSPC-derived proviral 
reservoir, it is unlikely that we could have identified identical HSPC-derived and plasma 
virus sequences since induction of viral outgrowth from an infected HSPCs likely also lead 
to the death and elimination of that cell and proviral sequence from the HSPC reservoir. 
On the other hand, extensive evidence for the clonal expansion of the rCD4+ T cell reservoir 
has been described (Chomont et al., 2009; Cohn et al., 2015; Maldarelli et al., 2014; 
Simonetti et al., 2016; Vandergeeten et al., 2012). In two of these studies, the authors 
present evidence that homeostatic proliferation of rCD4+ T cells is at least one mechanism 




Interestingly, in vitro induction of homeostatic proliferation in a subset of latently-infected 
rCD4+ T cells has failed to induce HIV reactivation (Bosque et al., 2011; Wang et al., 
2018). Therefore, it is possible that homeostatic proliferation and self-renewal of HSPCs 
may not reactivate HIV gene expression as potently as myeloid differentiation and allow 
for the expansion of a clonal HSPC reservoir of persistent HIV. Future studies looking at 
significantly more patient-derived HSPCs will be more powered to determine whether the 
HSPC-derived proviral reservoir is indeed unique as we have described or does establish a 
pool of clonally-expanded HIV-infected HSPCs. 
 
Evidence in support of an HSPC origin for part of the HIV reservoir 
One explanation for the identification of identical sub-genomic proviral sequences 
within HSPCs and other cellular compartments is coincidental infection of these different 
cells with genetically similar virus. We identified a 112 bp deletion of a portion of the HIV 
5’ LTR found within proviral sequences from a CHIP and PPC sequences that is predicted 
to allow proviral viral gene expression and outgrowth, but render newly produced virus 
non-infectious due to the deletion of the pbs, which is necessary for reverse transcription 
initiation in subsequent infection events. Therefore, it is most likely that this clonal viral 
reservoir within CHIPs originates from an initial infection event of an HSPC that then 
differentiated to give rise to a pool of mature peripheral blood cells. Further proliferation 
of these mature cellular reservoirs of HIV may further expand this CHIP (Figure 4.1). 
The observation of identical CHIP and PPC sequences with a signature deletion 
spanning the pbs raises two intriguing possibilities to explain this discovery. First, the 




homeostatic T cell proliferation, and antigenic-mediated T cell proliferation would yield 
increasingly more proviral clones. Each of these expanded clones has the potential to 
stochastically provide the necessary stimuli for HIV latency reversal and lead to viral 
outgrowth. Therefore, the likelihood of a CHIP contributing to a PPC is directly correlated 
to the population of the CHIP (Figure 4.1). 
Second, deletion of the HIV pbs in these CHIPs may promote greater basal viral 
gene transcription and outgrowth. A number of studies have demonstrated trans-acting 
factor-mediated, pbs-dependent repression of basal gene transcription of related 
retroviruses murine leukemia viruses (MLVs) in murine embryonic stem cells (Wolf et al., 
2008a; Wolf and Goff, 2008; Wolf and Goff, 2009; Wolf et al., 2008b). Furthermore, 
disruption of the 18 bp pbs sequence even by a single nucleotide mutation near the 3’ end 
of the motif has been shown to promote MLVs gene expression (Barklis et al., 1986). Our 
group has already begun designing experiments to test the hypothesis that the HIV pbs 
mediates viral gene repression through an, as yet unidentified, trans-factor, which limits 
robust viral outgrowth in vivo. We plan to perform in vitro experiments to compare the 
effects of pbs mutations on HIV gene expression in transfected HSPCs and CD4+ T cells 
with and without stem cell-like characteristics from healthy donors (Buzon et al., 2014; 
Cieri et al., 2013; Gattinoni et al., 2011). In addition, sequencing 5’ HIV LTRs of donor 
proviruses from various cell types has already begun. By accumulating these sequences of 
the non-coding region of HIV proviruses, we can investigate whether there is a correlation 
between 5’ LTR mutations, especially within the pbs, and the size of the pool of genetically 




Potent latency reversal as a means to reduce the HIV reservoir 
Class 1-selective HDIs induce potent HIV latency reversal when combined with the PKC 
agonist bryostatin-1 
In chapter 3, I described our work investigating the relative abilities of pan-HDIs 
and class 1-selective HDIs to potently reverse HIV latency and promote elimination of 
infected cells. We found that, in our model of HIV latency, class 1-selective HDIs were 
superior to pan-HDIs in their ability to induce potent viral gene expression. We also 
showed that class 1-selective HDIs, but not pan-HDIs acted additively with bryostatin-1 to 
induce the most robust viral outgrowth from our latently infected cells and from patient-
derived rCD4+ T cells. Furthermore, we provide evidence that inhibition of important pro-
viral cellular factors is unique feature of pan-HDI treatment. 
 Our model of HIV latency within HSPCs is unique from those established in 
primary CD4+ T cells in that we reliably obtain a large population of latently-infected 
primary cells that have not been manipulated beyond magnetic cell sorting with which to 
perform our experiments (Bosque and Planelles, 2009; Saleh et al., 2007; Swiggard et al., 
2005; Tyagi et al., 2010; Yang et al., 2009). Nevertheless, our results for the effects of 
HDIs alone on HIV latency reversal are consistent with previous reports, which 
demonstrate consistent reactivation of latent HIV from various cell line and primary CD4+ 
T cell models of HIV latency (Archin et al., 2009a; Archin et al., 2009b; Savarino et al., 
2009; Wei et al., 2014; Wightman et al., 2013; Ylisastigui et al., 2004). Most of these 
studies; however, measured HIV latency reversal by the frequency of infected cell that bore 
reactivated virus rather than the quality or potency of the reactivation that was induced. 




in a relatively smaller frequency of latently-infected cells compared to pan-HDIs and the 
remarkable effect of entinostat on potent viral protein production went unappreciated and 
unreported (Savarino et al., 2009; Wightman et al., 2013). 
While we report that reactivation of HIV latency in HSPCs by some proposed LRAs 
is consistent with effects observed in CD4+ T cell models, it is possible that other candidate 
LRAs may only be effective in certain infected cell types. We have previously shown that 
P-TEFb levels are sufficiently high to allow viral gene expression in HSPCs; however, 
HIV latency with these cells is maintained by very low levels of NF-κB. Therefore, when 
the P-TEFb activating agent, HMBA, which has shown activity in CD4+ T cell models of 
HIV latency, was used to treat latently-infected HSPC we observed no reactivation of HIV 
latency (McNamara et al., 2012). We have also discovered that disulfiram does not affect 
HIV latency in HSPCs, despite purported effects on latently-infected CD4+ T cells (Doyon 
et al., 2013; Mohammadi et al., 2014; Xing et al., 2011). Collectively, our results support 
the use of latency model systems in multiple, relevant cell types to comprehensively test 
the efficacy of candidate LRAs. 
One major limitation of our study and many others is the use of supratherapeutic 
levels of candidate LRAs. Current evidence for the use of bryostatin-1 to reverse HIV 
latency has been demonstrated using concentrations almost 100-fold higher than the 
average maximum serum level of bryostatin-1 observed in patients treated with a safe dose. 
Moreover, treatment of HIV-infected individuals with this safe dose of bryostatin-1 
demonstrated no effect on HIV gene expression or the viral reservoir in vivo (Gutierrez et 
al., 2016). We show that at 10 µM, class 1-selective HDIs can potently reverse HIV latency; 




with currently defined safe dosage (Batlevi et al., 2016; Gore et al., 2008; Siu et al., 2008). 
Therefore, while these proof-of-principle studies are important in delineating potentially 
effective mechanisms to achieve potent latency reversal, it is important to perform 
additional studies to understand the practical limitation of these findings and try to develop 
safer, effective LRAs. Fortunately, there is a clear path to develop clinically safe and 
potentially effective LRAs based on the knowledge from studies using compounds at 
supratherapeutic levels. The efficacy of bryostatin-1 as a single LRA has lead at least one 
group to chemically engineer and create bryostatin-1 analogs (‘bryologs’), which have 
demonstrated significantly greater potency for both PKC agonism and HIV latency reversal 
in cell and mouse models of HIV latency (DeChristopher et al., 2012; Marsden et al., 2017). 
Our data provide the foundation for similar class 1-selective HDI derivative 
development and discovery. The likelihood that such experiments and studies will occur 
receive the greatest support from those interested in the use of class 1-selective HDIs for 
the treatment of various cancers. As a relatively novel category of HDI, class 1-selective 
HDIs are underrepresented within the current pharmacopeia of anticancer treatment 
options (Li and Seto, 2016). However, their relative efficacy to suppress and kill specific 
types of cancerous cells and tumors has inspired the ongoing development and discovery 
of novel agents (Delcuve et al., 2013). Recently, largazoles and largazole derivatives were 
identified as a family of microbial-derived class 1-selective HDAC inhibitors that have 
potent anti-cancer activity and potently reactivate HIV in multiple cell line models of HIV 
latency at concentrations within the nanomolar range (Bui et al., 2017; Liu et al., 2010). 
However, the authors of this latter study failed to test the ability of largazole derivatives to 




discussed below, this study is limited in its relevance to the search for effective LRAs, but 
provides promising proof-of-principle that novel class 1-selective HDIs can be discovered 
and consistently induce potent HIV reactivation at least in in vitro models of latency. 
We also observed disparate effects of class 1-selective HDIs on intracellular HIV 
protein production and viral outgrowth in our model of HIV latency in HSPCs. While 
entinostat induced the most robust viral protein production of any single LRA tested, alone 
entinostat demonstrated relatively weak induction viral outgrowth from cells treated in 
exactly the same manner. One explanation is that despite the potency of viral protein 
production induced by entinostat, a critical threshold of cellular viral protein abundance 
necessary for efficient viral outgrowth was not achieved. However, treatment with the PKC 
agonist bryostatin-1 alone was sufficient to induce significant viral outgrowth despite 
inducing relatively lower levels of viral protein. This observation may be related to the 
relative effects of entinostat and bryostatin-1 on NF-κB activation, which is a limiting 
factor for robust viral gene expression in HSPC (McNamara et al., 2012). Therefore, 
entinostat and other HDIs may, in fact, require additional stimuli that affect distinct 
pathways that promote efficient virion production and release. This mutual relationship 
between distinct categories of LRAs has also recently been demonstrated for HIV latency 
reversal using benzotriazole derivatives and IL-2 (Bosque et al., 2017). Thus, a rational 
approach to potent latency reversal using combinations of mechanistically unique LRAs 





Elimination of latently-infected cells is correlated with potency of latency reversal and can 
be achieved by the combination of a class 1-selective HDI plus bryostatin-1 
 Individual LRAs have been shown to be ineffective at inducing robust ex vivo viral 
outgrowth and reservoir reduction in vivo (Archin et al., 2014; Bullen et al., 2014; Elliott 
et al., 2014; Sogaard et al., 2015). Therefore, the use of combinations of mechanistically 
distinct drugs aims to achieve synergism and permit safe and effective latency reversal. In 
chapter 3, we demonstrate that combinations of mechanistically distinct LRAs achieved 
the greatest effect on viral protein production, outgrowth, and reduction of infected cells in 
our HSPC model of HIV latency. Because of the previously demonstrated failure of 
vorinostat and other HDACs to induce synergistic latency reversal in combinations with 
bryostatin-1 (Laird et al., 2015), a recent study focused on combinations of bryostatin-1 
and P-TEFb activating agents. Interestingly, the authors report that P-TEFb activating 
LRAs (HMBA and JQ1) significantly enhanced bryostatin-1-mediated HIV latency 
reversal from patient-derived PBMCs and CD4+ T cells. Using an in vitro model system 
of HIV latency, the authors also report that the ability of the combinations of bryostatin-1 
plus JQ1 or HMBA was, predictably dependent on NF-κB and P-TEFb activation (Darcis 
et al., 2015). These results, especially the need for activated NF-κB and P-TEFb is precisely 
the kind of logical approach that future studies of LRA combinations should adopt. 
 Given the data we present in chapter 3, an intriguing next step would be to test 
triple-drug combinations for their ability to synergistically induce HIV latency reversal. As 
Darcis et al. demonstrated, both compounds included in their most effective combinations 
positively contributed to synergistic HIV latency reversal by activating the pathway they 




activation of P-TEFb by JQ1 or HMBA, and modification of LTR-associated chromatin 
structure by class 1-selective HDIs may lead to even greater latency reversal than what 
either Darcis et al or we have observed (Figure 4.2). Issues of combined drug toxicity 
would be the greatest concern with triple-drug therapy; however, we demonstrated that 
treatment of latently-infected HSPCs with three compounds did not significantly affect cell 
viability. Moreover, many of the current cART regimens are composed of three-drug 
combinations. 
 A major assumption of the current approach to reduce the HIV reservoir by latency 
reversal is that some of the infected cells will be cleared due to a robust anti-HIV 
immunological response by CTLs. However, as I discussed in chapter 1, the HIV accessory 
protein Nef limits MHC-I-dependent presentation of viral antigen on the cell surface, 
thereby evading CTL detection and elimination (Collins et al., 1998). There is no logical 
reason to assume that cellular reservoirs that bear reactivated, replication-competent HIV 
would behave any differently than the actively infected cells used to discover this 
paradigm. Indeed, we now have demonstrated, for the first time to our knowledge, that 
there is a direct correlation between the potency of viral reactivation and Nef-dependent 
downmodulation of MHC-I. Therefore, the most potent LRAs and LRA combo are also 
the most likely to most potently limit robust CTL responses against the infected cell. 
Interestingly, replication-defective proviruses that could be induced to at least express viral 
antigen, did render their reservoirs susceptible to CTL-mediated killing (Pollack et al., 
2017). Interestingly, none of the defective proviruses that this group characterized were 
able to express Nef based on the lack of CD4 downmodulation on primary CD4+ T cells 




demonstrated that patient-derived rCD4+ T cells harboring replication-competent provirus 
exhibit an inherent resistance to elimination by CTLs even when stimulated with potent T 
cell activating stimulus (Huang et al., 2018). Consistent with previous data describing an 
HIV genome mutation hotspot in nef (Bruner et al., 2016), Huang et al. report a remarkably 
high frequency of hypermutated nef sequences within genomes that contained intact gag 
open reading frames, leading them to propose that these defective proviruses are 
preferentially eliminated, while intact proviruses may promote Nef-dependent reservoir 
immunoevasion. Thus, development of small molecules that inhibit Nef activity is an 
exciting and important field of research. To date, very few candidates have been described. 
Moreover, their true effectiveness in promoting reservoir elimination has not been tested 
(Emert-Sedlak et al., 2016; Mujib et al., 2017). Our group has also been searching for small 
molecules that antagonize HIV Nef and has recently identified 4 highly-purified, natural 
product extracts that have demonstrated potent inhibition of Nef-mediated 
downmodulation of MHC-I. It will be interesting when these highly-purified natural 
product extracts are fully-characterized and used in assays to assess their ability to promote 
immune elimination of infected cells. 
Without an effective Nef inhibitor, immune elimination of the HIV reservoir is 
limited by the activity of HIV Nef. An alternative process that may reduce the viral 
reservoir is viral cytopathicity. Because this process is viral protein-dependent, the most 
potent viral cytopathicity would likely occur in the context of the most potent viral latency 
reversal. Indeed, we demonstrated that there is a direct correlation between potency of 
induced latency reversal and elimination of infected HSPC in our in vitro model. These 




CD4+ T cells treated with vorinostat (Shan et al., 2012). On the other hand, treatment of 
these cells with T cell activating stimuli induced relatively more potent viral latency 
reversal, leading to cytopathicity and a dramatic reduction of infected cells from culture 
(Shan et al., 2012). This study raised the alarming proposal that candidate LRAs that do 
not induce global T cell activation may not be potent enough to cause viral cytopathicity 
and reduce the viral reservoir. However, our results and those of at least one other group 
have demonstrated in vitro elimination of infected primary cells using distinct 
combinations of LRAs that are unlikely to induce global T cell activation (Bosque et al., 
2017). Therefore, it may, indeed be possible to achieve reservoir reduction and avoid toxic 
global T cell activation. However, whether these in vitro effects on infected cells will 
translate into in vivo efficacy is one of the most important, as yet, unanswered questions 
raised by our results. 
 
Pan-HDIs inhibit cellular pro-viral factors and suppress potent HIV latency reversal 
 Finally, we made the discovery that pan-HDIs suppress potent viral latency 
reversal, which is correlated with their inhibitory effects on important pro-viral cellular 
factors (NF-κB and Hsp90). Previous studies using pan-HDIs, even in combination with 
bryostatin-1 were likely unable to observe this effect since the potency of latency reversal 
induced by bryostatin-1 is relatively lower than that achieved with class 1-selective HDIs 
plus bryostatin-1. Therefore, the dynamic range over which the inhibitory effect of pan-
HDIs could be observed was dramatically smaller (Darcis et al., 2015; Laird et al., 2015). 
Indeed, even in our HSPC model system of HIV latency, we observed a very small 




 HDACs mediate de-acetylation of many non-histone substrates. Our work has 
bridged a gap in our knowledge on how pan-HDIs affect HIV gene expression by 
promoting Hsp90 acetylation (Anderson et al., 2014; Bali et al., 2005; Joshi et al., 2016; 
Li et al., 2011; Muhlenberg et al., 2009; O'Keeffe et al., 2000; Pan et al., 2016; Roesch et 
al., 2012; Scroggins et al., 2007). In addition to cellular factors affected by HDIs, thorough 
investigation of the “acetylome” of viral proteins within actively infected cells may lead to 
a more efficient search for highly-effective HDI LRAs. Based on our current knowledge 
of viral proteins whose functions are significantly affected by acetylation, the regulatory 
protein Tat is the most attractive candidate with which to initiate these studies. Tat activity 
is exquisitely regulated by the acetylation status of two key lysine residues (Dormeyer et 
al., 2003; Dorr et al., 2002; Kaehlcke et al., 2003; Mujtaba et al., 2002; Ott et al., 2004; Ott 
et al., 1999). Both the class II HDAC (HDAC6) and the class III HDAC (Sirt1) play roles 
in deacetylating Tat at specific times during Tat-mediated transcription transactivation 
(Huo et al., 2011; Pagans et al., 2005). Therefore, understanding the effects of HDIs on this 
viral protein that is critical for robust viral gene expression would be of great interest and 
important to designing novel and even more effective candidate LRAs. 
 Beyond their effects on HIV latency and gene expression, HDIs may have 
pleiotropic effects on treated cells and tissues, which may confound effective reservoir 
reduction. Indeed, several studies have now reported that pan-HDIs, especially vorinostat, 
has multiple deleterious effects with respect to CD8+ T cell and CTL viability, mobility, 
and immune function; and to NK cell function (Garrido et al., 2016; Jones et al., 2014; 
Pace et al., 2016). Moreover, another pan-HDI panobinostat was recently shown to 




inflammatory responses by whole blood induced by LPS. These results provide further 
evidence that pan-HDIs may limit potent HIV latency reversal and reservoir elimination 
by suppressing activation of signal pathways necessary for potent viral gene expression 
(Cary et al., 2016; Williams et al., 2007) and increasing the proportion of immune-
suppressive Tregs in vivo (Tang and Bluestone, 2008). Therefore, it is critical to elucidate 
the specific effects of class 1-selective HDIs on immune cell function in order to better 
understand their practical potential as effective LRAs that may lead to HIV reservoir 
reduction. 
 Finally, throughout this entire section I’ve described data concerning very specific 
experimental outcomes; however, given our apparent lack of substantial knowledge on the 
diverse effects of different categories of LRAs on primary immune cells, more 
collaborative and unbiased studies are called for. The ability of unbiased and “-omic” 
studies to significantly contribute to the knowledge of a topic is best exemplified by some 
of the work performed and ongoing on the topic of elite controllers of HIV (Fellay et al., 
2009; Fellay et al., 2007; International et al., 2010; Pelak et al., 2010; Zhang et al., 2018; 
Zhang et al., 2017). One study has compared the “acetylomes” within various cancer cell 
lines treated with entinostat or vorinostat and the results of this work informed our 
investigation of the effects of HDIs on Hsp90 activity (Choudhary et al., 2009). Similar 
unbiased analyses within primary cells treated with different HDIs or other candidate LRAs 
may shed light on processes affected by these treatments that may affect latency reversal 





In this dissertation, I have presented work from our group that has investigated the 
contribution of HSPCs to the HIV reservoir and residual viremia. We found that, compared 
to PBMC-derived HIV proviruses, proviruses detected in HSPCs are uniquely represented 
more frequently within sequences of residual plasma virus and are associated with clusters 
of HSPC-associated identical proviruses (CHIPs). Furthermore, we identified a signature 
deletion of the HIV primer binding site within a CHIP and PPC sequences that provides 
the strongest evidence, thus far, in support of HSPCs as an origin for part of the functional 
and clinically-significant HIV reservoir. As a result of these discoveries, I have modelled 
the possible fates of HIV-infected HSPCs in vivo, including the contribution and expansion 
of the HIV reservoir (Figure 4.1). 
In this dissertation, I have also presented our work investigating of the efficacy of 
categories of HDIs to reverse HIV latency and promote elimination of latently-infected 
cells. We found that, compared to broadly-acting pan-HDIs, class 1-selective HDIs 
reversed HIV latency more potently and were able to act additively with the PKC agonist 
bryostatin-1 to achieve greater HIV reactivation both in latently-infected HSPCs and in 
patient-derived rCD4+ T cells. Furthermore, we demonstrate that potent HIV latency 
reversal induced by the combination of a class 1-selective HDI plus bryostatin-1 lead to 
the greatest reduction of HIV-infected HSPCs in our in vitro model of HIV latency reversal 
and reservoir elimination. We also confirmed our hypothesis that the relative impotency of 
pan-HDIs in HIV latency reversal is due, in part, to their inhibitory effects on cellular 
factors necessary for robust viral gene expression (Figure 4.2). These findings suggest a 




either ex vivo or in vivo, as well as provide a more rational, targeted, and effective 
alternative for potent latency reversal using class 1-selective HDIs. 
Together, the findings described in this dissertation provide novel information that 
will inform future research on the HIV reservoir and strategies to eliminate it from infected 
people. By this, we may be able to significantly improve therapy for HIV infection and 





Figure 4.1. Proposed model of the contribution of clusters of HSPC-associated 
identical proviruses (CHIPs) to the HIV reservoir. HSPCs can be infected in vivo and 
can bear persistent HIV provirus for several years. Possible fates for an infected HSPC are 
summarized here.  (1) As a long-lived cell, an HSPC that bears a latent provirus can avoid 
elimination due to active HIV infection and can be maintained in its bone marrow niche. 
(2) Alternatively, homeostatic proliferation may expand the HSPC-derived proviral 
reservoir. However, there is little evidence for clonal HSPC-derived proviral sequences. 
(3) Latently-infected HSPCs may also be reactivated and directly contribute to peripheral 
plasma virus. In vitro, HSPCs are capable of robust viral outgrowth. Demonstrating ex vivo 
viral outgrowth from infected HSPCs from optimally-treated people; however, is, 
currently, impractical due to the large number of HSPCs required to properly perform the 
assay. (4) Finally, infected HSPCs can differentiate into mature daughter cells including 
CD4+ T cells. The possible fates of these CD4+ T cells is shown here and discussed in 
(Sebastian and Collins, 2014). Propagation of the HSPC-derived HIV provirus to 4 or more 
mature daughter cells represents, as we have defined in our work, a cluster of HSPC-
associated identical proviruses (CHIPs). As described in Chapter 2, in cases where a 
predominant plasma virus clone (PPC) can be attributed to a cellular proviral source, it is 





Figure 4.2. Summary of mechanisms of HIV latency reversal and effects of pan-HDIs 
on Hsp90 and NF-κB. As discussed in Figure 1.5, HIV gene transcription is regulated by 
several host and viral factors. Reactivation of HIV gene expression has been demonstrated 
using compounds (white polygons) that perturb these known mechanisms of HIV gene 
regulation. Activation of the NF-κB pathway can be achieved by the PKC agonist 
bryostatin-1 or by TNF-α. P-TEFb can become activated and made available for Tat-
mediated transactivation by induction of its release from its inhibitory complex in the 
cytoplasm by HMBA or from the competitive antagonist BRD4. Both pan-HDIs and class 
1-selective HDIs affect class 1 HDAC isoforms to promote histone acetylation and 
euchromatic structure at the HIV promoter. As a result of their relatively broad range, pan-
HDIs also affect non-histone targets that are regulated by non-class 1 HDAC isoforms. In 
Chapter 3, I present evidence that the pan-HDI vorinostat modestly inhibits NF-κB 
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Treatment of latently-infected HSPCs with entinostat plus bryostatin-1 leads to a 
reduction of the proviral load 
 In Chapter 3, I investigated the ability of candidate LRAs and LRA combinations 
to induce robust viral outgrowth and lead to the death and reduction of HIV-infected 
HSPCs. We demonstrated that the combination of entinostat plus bryostatin-1 induced the 
greatest reduction of the frequency of residual infected HSPCs and was the only LRA 
regimen that induced a significant reduction of the residual, TNF-α inducible reservoir 
(Figure 3.7). However, it is possible that these results could be explained by differences in 
rates of reversion to latency and sensitivity to TNF-α stimulus. Therefore, we next sought 
to quantify the number of integrated HIV proviruses within HSPCs that had been treated 
as described in Figure 3.7 using a quantitative PCR assay for Alu-HIV LTR. 
 Alu elements are the most numerous repetitive sequences that represent about 10% 
of the human genome. Alu sequences are random distributed throughout the genome about 
5,000 bp apart and in random orientation (Lander et al., 2001). Therefore, several Alu PCR 
assays have been developed to amplify and quantify integrated HIV proviral genomes 
(Eriksson et al., 2013; Graf and O'Doherty, 2013; Liszewski et al., 2009; Vandergeeten et 
al., 2014). Amplification is performed using primers specific for the Alu element and the 
HIV LTR, so that proviruses integrated near Alu elements may be amplified and detected 




 To determine whether infected HSPCs from experiments described in Figure 3.7 
were being cleared from cultures faster with treatment that most potently induced HIV 
latency reversal, we performed qPCR assays on Alu-HIV amplicons that were generated 
as previously described (Vandergeeten et al., 2014). Consistent with our results in Figure 
3.7, we observed the greatest reduction in the number of Alu-HIV amplicons detected in 
cultures of latently-infected HSPCs that were treated with entinostat plus bryostatin-1 
(Figure 0.1). This result provides additional evidence in support of our conclusion that the 
combination of entinostat plus bryostatin-1 leads to the death and elimination of infected 
HSPCs from our in vitro model system of HIV latency. It is possible that these results may 
be explained by differential rates of proliferation of HSPC cell subsets within each 
treatment condition. This could be addressed in future experiments using a lipophilic, cell-
tracking dye such as PKH26, whose fluorescence intensity decreases 2-fold with each 
symmetric cellular division. Moreover, as Alu elements exist throughout the human 
genome in both orientations, it will be necessary that future repeats of this experiment also 
include controls where HIV (Alu only) or Alu (HIV only) primers are left out to appreciate 
the contribution of first round Alu-Alu amplicons and background, unintegrated HIV DNA. 
Methods 
Quantification of integrated HIV DNA 
DNA from treated HSPCs was isolated using the QIAGEN DNeasy Blood and 
Tissue Kit according to the manufacturer’s protocol (QIAGEN).  
Integrated HIV genomes were amplified and quantified as previously described 




Alu-specific primers with 5’ Lambda T sequence tags and one HIV LTR-specific primer. 
The PCR cycle conditions were: 8 min at 95°C, and 12 cycles of amplification (95°C for 1 
min, 55°C for 1 min, 72°C for 10 min), followed by 15 min at 72°C. The second round of 
PCR were performed using the TaqMan Gene Expression Mastermix (Applied 
Biosystems), primers specific for the Lambda T DNA sequence tag and the HIV U5 LTR, 
and a probe specific for the R region of the HIV LTR. All reactions were performed on an 
Applied Biosystems 7300 thermocycler, with the following cycling conditions: 95°C for 
10 minutes, then 45 cycles of 95°C for 15 seconds followed by 60°C for 60 seconds 
An assay standard curve was generated using DNA from ACH-2 cells which harbor 
a single copy of integrated HIV provirus (Clouse et al., 1989). Relative cell numbers were 
quantified using TaqMan Gene Expression Mastermix with the primers and probes specific 
for the human beta-globin (Forward: 5’-CCCTTGGACCCAGAGGTTCT-3’; Reverse: 5’-
CGAGCACTTTCTTGCCATGA-3’; Probe:5’-VIC-ATCTGTCCACTC-







Figure 5.1. Treatment of latently-infected HSPCs with entinostat plus bryostatin-1 
leads to a significant decrease in the proviral burden. Box and whisker plot (5-95 
percentiles) of Alu-HIV amplicons detected by qPCR from DNA samples isolated treated 
HSPCs as described in Figure 3.7. Data were normalized to DMSO, n=4). P values were 
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